[go: up one dir, main page]

NZ588080A - 2-Aza-bicyclo[2.2.1]heptane derivatives - Google Patents

2-Aza-bicyclo[2.2.1]heptane derivatives

Info

Publication number
NZ588080A
NZ588080A NZ588080A NZ58808009A NZ588080A NZ 588080 A NZ588080 A NZ 588080A NZ 588080 A NZ588080 A NZ 588080A NZ 58808009 A NZ58808009 A NZ 58808009A NZ 588080 A NZ588080 A NZ 588080A
Authority
NZ
New Zealand
Prior art keywords
thiazole
carboxylic acid
phenyl
aza
bicyclo
Prior art date
Application number
NZ588080A
Inventor
Hamed Aissaoui
Christoph Boss
Ralf Koberstein
Thierry Sifferlen
Daniel Trachsel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NZ588080A publication Critical patent/NZ588080A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Disclosed is a 2-aza-bicyclo[2.2.1]heptane derivative of formula (I), or a salt thereof, where n is 0 or 1, A and B are each optionally substituted aryl or heterocycle, and the other substituents are as defined in the specification. Also disclosed is the use of the compound for treating selected all types of sleep disorders, stress related syndromes, psychoactive substance use and abuse, cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, and eating or drinking disorders.

Description

New Zealand Paient Spedficaiion for Paient Number 588080 Received at IPONZ on 20-Mar-2012 2-Aza-bicyclor2.2.11heptane derivatives The present invention relates to 2-aza-bicyclo[2.2.1]heptane derivatives of formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including 5 processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as orexin receptor antagonists.
Orexins (orexin A or OX-A and orexin B or OX-B) are novel neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino 10 acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to G-protein-coupled receptors (OXi and OX2 receptors). The orexin-1 receptor (OXi) is selective for OX-A, and the orexin-2 receptor (OX2) is capable to bind OX-A as well as OX-B. Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in 15 the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al., Cell, 1998, 92, 573-585). On the other hand, it was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to narcolepsy as well as insomnia and other sleep disorders (Chemelli R.M. et al., Cell, 1999, 98, 437-451).
Orexin receptors are found in the mammalian brain and may have numerous implications 20 in pathologies as known from the literature.
The present invention provides 2-aza-bicyclo[2.2.1]heptane derivatives, which are non-peptide antagonists of human orexin receptors. These compounds are in particular of potential use in the treatment of e.g. eating disorders, drinking disorders, sleep disorders, or cognitive dysfunctions in psychiatric and neurologic disorders.
Up to now, several low molecular weight compounds are known having a potential to antagonise either specifically OXi or OX2, or both receptors at the same time. Piperidine derivatives useful as orexin receptor antagonists are disclosed in W001/096302. N-Aroyl cyclic amine derivatives are disclosed in W002/090355.
The present invention describes for the first time 2-aza-bicyclo[2.2.1]heptane derivatives 30 as orexin receptor antagonists.
Received at IPONZ on 20-Mar-2012 2 1) A first aspect of the invention relates to compounds of formula (I) wherein the stereogenic centers are in absolute (lR,3S,4S)-configuration wherein A represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (c3-6)cycloalkyl, (c2-6)alkinyl, (Ci_4)alkoxy, NR2R3, halogen, (Ci-4)alkoxy-(Ci_4)alkoxy, and unsubstituted or independently mono- or 10 di-substituted phenyl or pyridyl, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, fluorine and chlorine; B represents an aryl- or heterocyclyl-group, wherein the aryl or heterocyclyl is unsubstituted or independently mono-, di-, or tri-substituted, wherein the substituents are 15 independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, -NR4R5, -NHS02-(Ci_4)alkyl, -N(R4)C(0)R5 and halogen; or B represents a benzo[l,3]dioxolyl group. n represents the integer 0 or 1; R1 represents heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di-, or tri-20 substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, halogen, trifluoromethyl and -NR4R5; or R1 represents a lH-indenyl, a 2,3-dihydro-benzofuranyl-, a benzo[l,3]dioxolyl-, a 2,3-dihydro-benzo[l,4]dioxinyl-, a 4//-benzo[l,3]dioxinyl-, a 2//-chrorncnyl-, a chromanyl-, a 2,3-dihydro-thieno[3,4-b][l,4]dioxinyl-, a 3,4-dihydro-2//-benzo[l,4]oxazinyl- or a 25 2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuranyl-group; wherein said groups are A \ B Formula (I) Received at IPONZ on 20-Mar-2012 3 unsubstituted, mono- or di-substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen; R2 represents hydrogen or (Ci_4)alkyl; R3 represents hydrogen or (Ci_4)alkyl; or R2 and R3 together with the nitrogen to which they are attached to form a pyrrolidine ring; R4 represents hydrogen or (Ci_4)alkyl; and R5 represents hydrogen or (Ci_4)alkyl; wherein the term "heterocyclyl" means a 5- to 10-membered monocyclic or bicyclic 10 aromatic ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulphur. 2) A second aspect of the invention relates to compounds of formula (I) according to embodiment 1), which compounds are also compounds of formula (IP), wherein the stereogenic centers are in absolute (lR,3S,4S)-configuration: A \ B Formula (IP) wherein A represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono- or di-substituted, wherein the substituents are independently selected 20 from the group consisting of (Ci_4)alkyl, (C3.6)cycloalkyl, (C2-6)alkinyl, (Ci_4)alkoxy, NR2R3, halogen, and unsubstituted or independently mono- or di-substituted phenyl or pyridyl, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, fluorine and chlorine; B represents an aryl- or heterocyclyl-group, wherein the aryl or heterocyclyl is 25 unsubstituted or independently mono-, di-, or tri-substituted, wherein the substituents are Received at IPONZ on 20-Mar-2012 4 independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, -NR4R5, -NHS02-(Ci_4)alkyl, -N(R4)C(0)R5 and halogen; n represents the integer 0 or 1; substituted wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci_4)alkoxy, halogen, trifluoromethyl and -NR4R5; or R1 represents a lH-indenyl, a 2,3-dihydro-benzofuranyl-, a benzo[l,3]dioxolyl-, a 2,3-dihydro-benzo[l,4]dioxinyl-, a 4//-benzo[l,3]dioxinyl-, a 2//-chromeny1-, a chromanyl-, a 2,3-dihydro-thieno[3,4-b][l,4]dioxinyl-, a 3,4-dihydro-2//-benzo[l,4]oxazinyl- or a 10 2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuranyl-group; wherein said groups are unsubstituted, mono- or di-substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen; R2 represents hydrogen or (Ci_4)alkyl; and R3 represents hydrogen or (Ci_4)alkyl; R4 represents hydrogen or (Ci_4)alkyl; and R5 represents hydrogen or (Ci_4)alkyl.
The invention also relates to salts, especially pharmaceutically acceptable salts, of the compounds of formula (I).
The compounds of formula (I) may contain one or more stereogenic or asymmetric centers, 20 such as one or more asymmetric carbon atoms. The compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
In this patent application, an arrow shows the point of attachment of the radical drawn. For example, the radical drawn below is the 5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl group.
The term "halogen" means fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine, most preferably fluorine.
R1 represents heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di-, or tri- Received at IPONZ on 20-Mar-2012 The term "(Ci.4)alkyl", alone or in combination, means a straight-chain or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of (Ci_4)alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec.-butyl or tert.-butyl. Preferred are methyl and ethyl. Most preferred is methyl.
The term "(C2-6)alkinyl", alone or in combination, means a straight-chain or branched-chain alkinyl group with 2 to 6 carbon atoms. Examples of (C2-6)alkinyl groups are ethinyl, 1-propinyl, 1-butinyl, 3-methyl-l-butinyl, 1-pentinyl, 3,3-dimethyl-l-butinyl, 3-methyl-1-pentinyl, 4-methyl-1-pentinyl or 1-hexinyl. Preferred is ethinyl.
The term "(C3_6)cycloalkyl", alone or in combination, means a cycloalkyl group with 3 to 6 10 carbon atoms. Examples of (C3-6)cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Preferred is cyclopropyl.
The term "(Ci_4)alkoxy", alone or in combination, means a group of the formula (Ci_4)alkyl-0- in which the term "(Ci.4)alkyl" has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy or tert.-15 butoxy. Preferred are methoxy and ethoxy. Most preferred is methoxy.
The term "aryl", alone or in combination, means a phenyl or a naphthyl group. Preferred is a phenyl group. The aryl group is unsubstituted or substituted as explicitly defined.
In case "A" represents "aryl" the term means the above-mentioned group which is unsubstituted (preferred) or mono- or di-substituted, wherein the substituents are 20 independently selected from the group consisting of (Ci_4)alkyl, (C3-6)cycloalkyl, (C2-6)alkinyl, (Ci_4)alkoxy, NR2R3, halogen, (Ci_4)alkoxy-(Ci_4)alkoxy, and unsubstituted or independently mono- or di-substituted phenyl or pyridyl, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, fluorine and chlorine. Notably, the substituents are 25 independently selected from the group consisting of (Ci_4)alkyl, (C3.6)cycloalkyl, (C2. 6)alkinyl, (Ci_4)alkoxy, -NR2R3, halogen, and unsubstituted or independently mono- or di-substituted phenyl or pyridyl, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, fluorine and chlorine. Preferably the substituents are independently selected from the group 30 consisting of (Ci_4)alkyl, (C3.6)cycloalkyl, (Ci_4)alkoxy, and -NR2R3. A preferred example wherein "A" represents "aryl" is unsubstituted phenyl. In addition to the above-mentioned Received at IPONZ on 20-Mar-2012 6 substituents, the substituent "A" is also substituted by the substituent "B", wherein B is preferably attached in ortho position to the point of attachment of the carbonyl group which links A to the 2-aza-bicyclo[2.2.1]heptane moiety.
In case "B" represents "aryl" the term means the above-mentioned group which is 5 unsubstituted or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, -NR4R5, -NHS02-(Ci_4)alkyl, -N(R4)C(0)R5 and halogen. Notably, the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_ 4)alkoxy, trifluoromethyl, -NR4R5, -NHS02-(Ci_4)alkyl, -N(R4)C(0)R5 and halogen. 10 Preferred examples wherein "B" represents "aryl" are unsubstituted or mono-, di-, or tri-substituted phenyl (preferred unsubstituted, mono- or di-substituted phenyl, especially preferred unsubstituted or mono-substituted phenyl), wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl and halogen. In addition to the above-mentioned substituents, the 15 substituent "B" is attached to the substituent "A".
Examples wherein "B" represents "aryl" are phenyl, 3-methylphenyl, 4-methylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 3-methoxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3-trifluoromethylphenyl, 3-fluoro-2-methylphenyl, 3-fluoro-4-methylphenyl and 3-bromo-20 4-fluorophenyl. Preferred examples are phenyl, 3-methylphenyl, 4-methylphenyl, 3,4-dimethylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl and 3-bromo-4-fluorophenyl. In addition to the above-listed groups, further examples are 4-methoxyphenyl, 3,4-dimethoxyphenyl, and 3-trifluoromethoxyphenyl.
In case "A" and "B" both represent "aryl" the combination "A-B" preferably means a 25 biphenyl group which is unsubstituted or mono- or di-substituted for "A" and unsubstituted or mono-, di- or tri-substituted for "B", wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl and halogen. Preferred examples wherein "A" and "B" both represents "aryl" are biphenyl groups which are unsubstituted (preferred) or mono- or di-substituted for "A" and unsubstituted or mono-30 , di- or tri-substituted (preferred unsubstituted, mono- or di-substituted) for "B", wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl and halogen. Especially preferred examples wherein "A" and "B" both represents "aryl" are Received at IPONZ on 20-Mar-2012 7 biphenyl groups which are unsubstituted for "A" and mono-substituted for "B", wherein the substituent is halogen.
Examples of such a combination "A-B" are: The term "heterocyclyl", alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of such heterocyclyl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, 10 benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[l,5-a]pyridyl, pyrazolo[l,5-a]pyrimidyl, imidazo[l,2-ajpyridyl, pyrrolo[2,l-b] thiazolyl or imidazo[2,l-b]thiazolyl. The above-mentioned 15 heterocyclyl groups are unsubstituted or mono-, di-, or tri-substituted as explicitly defined.
In case "A" represents "heterocyclyl" the term means the above-mentioned heterocyclyl groups which are unsubstituted or mono- or di-substituted (preferred unsubstituted or mono-substituted) wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (C3-6)cycloalkyl, (C2-6)alkinyl, (Ci_4)alkoxy, NR2R3, halogen, (Ci_ 20 4)alkoxy-(Ci_4)alkoxy, and unsubstituted or independently mono- or di-substituted phenyl or pyridyl, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, fluorine and chlorine. Notably, the substituents are independently selected from the group consisting of (Ci_ 4)alkyl, (C3.6)cycloalkyl, (C2-6)alkinyl, (Ci_4)alkoxy, NR2R3, halogen, and unsubstituted or 25 independently mono- or di-substituted phenyl or pyridyl, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, fluorine and chlorine. Preferably the substituents are independently selected from the group consisting of (Ci_4)alkyl, (C3.6)cycloalkyl, (Ci_ 4)alkoxy, and -NR2R3. In a further preferred embodiment, in case "A" represents 30 "heterocyclyl" the term means a 5- to 6-membered (preferably 5-membered) monocyclic CI Received at IPONZ on 20-Mar-2012 8 heterocyclyl group as defined above (such as pyrimidinyl, pyrazinyl, oxazolyl, thiophenyl, or thiazolyl (notably pyrimidinyl, oxazolyl or thiazolyl); especially pyrimidinyl or thiazolyl; most preferred thiazolyl, especially thiazol-4-yl) which is unsubstituted or mono-substituted, wherein the substituent is selected from the group consisting of (Ci_4)alkyl, 5 (C3.6)cycloalkyl, (Ci_4)alkoxy and NR2R3. Preferred examples wherein "A" represents "heterocyclyl" are unsubstituted or mono-substituted heterocyclyl as mentioned above wherein the substituent is selected from (Ci_4)alkyl, (c3-6)cycloalkyl and NR2R3. In a sub-embodiment, in case A represents a pyrazinyl- or a thiophenyl group, such group is preferably unsubstituted. In addition to the above-mentioned substituents, the substituent 10 "A" is also substituted by the substituent "B", wherein B is preferably attached in ortho position to the point of attachment of the carbonyl group which links A to the 2-aza-bicyclo[2.2.1]heptane moiety.
Particular examples wherein "A" represents "heterocyclyl" are thiazol-4-yl, 2-methyl-thiazol-4-yl, 2-amino-thiazol-4-yl, 2-dimethylamino-thiazol-4-yl, 2-methyl-ethyl-amino-15 thiazole-4-yl, 2-diethylamino-thiazole-4-yl, 2-methylamino-thiazol-4-yl, 2-ethylamino-thiazol-4-yl, 2-(l-pyrrolidino)-thiazol-4-yl, 2-cyclopropyl-thiazol-4-yl, 2-methoxy-thiazol-4-yl, 2-ethoxy-thiazol-4-yl, and 2-(2-methoxy-ethoxy)-thiazole-4-yl, wherein B is attached in position 5 of the above thiazol-4-yl groups; 2-methyl-oxazol-4-yl, wherein B is attached in position 5 of the above oxazol-4-yl group; pyrazin-2-yl, wherein B is attached in 20 position 3 to the pyrazin-2-yl group; 2-methyl-pyrimidin-5-yl, wherein B is attached in position 6 to the pyrimidin-5-yl group; and thiophen-2-yl, wherein B is attached in position 3 of the above thiophen-2-yl group. In a sub-embodiment, particular examples are thiazol-4-yl, 2-methyl-thiazol-4-yl, 2-amino-thiazol-4-yl, 2-dimethylamino-thiazol-4-yl, and 2-cyclopropyl-thiazol-4-yl, wherein B is attached in position 5 of the above thiazol-4-yl 25 groups Preferred are 2-methyl-thiazol-4-yl, 2-dimethylamino-thiazol-4-yl and 2-cyclopropyl-thiazol-4-yl.
Received at IPONZ on 20-Mar-2012 In one embodiment, particular examples of groups wherein "A" represents "heterocyclyl' and one of the substituents is represented by "B" are: -#o J s N N h,NA >V 1 In a further embodiment and in addition to the above-listed groups, further examples of 5 such groups are: In a further embodiment and in addition to the above-listed groups, further examples of such groups are: HN N // CI Received at IPONZ on 20-Mar-2012 In a further embodiment and in addition to the above-listed groups, further examples of such groups are: In case "B" represents "heterocyclyl" the term means the above-mentioned heterocyclyl 5 groups which are unsubstituted (preferred) or mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, -NR4R5, -NHS02-(Ci_4)alkyl, -N(R4)C(0)R5 and halogen. Especially, the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, and halogen. Examples wherein "B" represents 10 "heterocyclyl" are thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyridazinyl, and pyrazinyl. In addition to the above-listed examples, a particular example is indanyl (notably indan-6-yl). In addition to the above-mentioned substituents, the substituent "B" is attached to the substituent "A".
In case R1 represents "heterocyclyl" the term means the above-mentioned heterocyclyl 15 groups which are unsubstituted or mono-, di-, or tri-substituted (preferred unsubstituted or mono- or di-substituted, especially preferred unsubstituted or mono-substituted) wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, halogen, trifluoromethyl and -NR4R5. In a further preferred embodiment, in case R1 represents "heterocyclyl" the term means the above-mentioned heterocyclyl groups 20 which are unsubstituted or mono-, di-, or tri-substituted (preferred unsubstituted or mono-substituted) wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci_4)alkoxy and halogen. In a further preferred embodiment, in case R1 represents "heterocyclyl" the term means the above-mentioned heterocyclyl groups which are unsubstituted or mono-, di-, or tri-substituted (preferred unsubstituted or mono-25 substituted) wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl. In a further preferred embodiment, in case R1 represents "heterocyclyl" the term means the above-mentioned heterocyclyl groups which are unsubstituted or mono-, di-, or tri-substituted (preferred unsubstituted or mono-substituted) wherein the substituent is methyl.
Received at IPONZ on 20-Mar-2012 11 In another embodiment, in case n represents the integer 1, preferred examples wherein "R1" represents "heterocyclyl" are unsubstituted or mono-, di-, or tri-substituted (preferred unsubstituted or mono-substituted) heterocyclyl; wherein the heterocyclyl is selected from the group consisting of isoxazolyl, thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, 5 benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, pyrrolo[2,l-b]thiazolyl, imidazo[l,2-a]pyridyl and imidazo[2,l-b]thiazolyl; notably, the heterocyclyl is selected from the group consisting of thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, 10 benzoisothiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, pyrrolo[2,l-b]thiazolyl, imidazo[l,2-a]pyridyl and (especially) imidazo[2,l-b]thiazolyl (especially the heterocyclyl is selected from thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, quinolinyl, pyrrolo[2,l-b]thiazolyl, imidazo[l,2-a]pyridyl and (especially) imidazo[2,l-b]thiazolyl); wherein the 15 substituents are independently selected from (Ci_4)alkyl, (Ci_4)alkoxy and halogen.
In another embodiment, in case n represents the integer 1, particular examples wherein "R1" represents "heterocyclyl" are pyrazol-3-yl, indol-2-yl, indol-3-yl, benzofuran-4-yl, indazol-3-yl, benzimidazol-2-yl, benzimidazol-5-yl, benzoxazol-4-yl, benzisoxazol-3-yl, benzthiazol-7-yl, quinolin-8-yl, pyrrolo[2,l-b]thiazol-7-yl, imidazo[l,2-a]pyridine-3-yl and 20 imidazo[2,l-b]thiazol-5-yl (especially imidazo[2,l-b]thiazol-5-yl). In addition to the above-listed examples, further examples are 5-ethyl-3-methyl-isoxazole-4-yl, 3-ethyl-5-methyl-isoxazole-4-yl, quinoxaline-5-yl, and benzo[d]isothiazol-3-yl. The above-mentioned heterocyclyl groups are unsubstituted, mono-, di-, or tri-substituted (preferred unsubstituted or mono-substituted), wherein the substituents are independently selected 25 from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen.
In particular, the above mentioned "heterocyclyl" groups as used for the substituent "R1" are preferably substituted as follows: pyrazolyl groups are di-substituted with (Ci_4)alkyl; indolyl groups are unsubstituted or di-substituted independently with (Ci_4)alkyl (especially methyl) or halogen; benzofuranyl groups are unsubstituted; indazolyl groups 30 are unsubstituted or mono-substituted with (Ci_4)alkyl (especially methyl); benzimidazolyl groups are mono- or di-substituted with (Ci_4)alkyl (especially methyl); benzoxazolyl groups are mono-substituted with (Ci_4)alkyl (especially methyl); benzisoxazolyl groups Received at IPONZ on 20-Mar-2012 12 are unsubstituted; benzthiazolyl groups are unsubstituted; quinolinyl groups are unsubstituted; pyrrolo[2,l-b]thiazolyl groups are mono-substituted with (Ci_4)alkyl (especially methyl); imidazo[l,2-a]pyridinyl groups are unsubstituted; and imidazo[2,l-b] thiazolyl groups are mono-substituted with (Ci_4)alkyl (especially methyl); further, 5 benzoisothiazolyl groups are unsubstituted; quinoxalinyl groups are unsubstituted; and isoxazolyl groups are di-substituted with (Ci_4)alkyl.
Particular examples wherein R1 represents "heterocyclyl" are: In a further embodiment, and in addition to the above-listed groups, further examples are: In another embodiment, in case n represents the integer 0, a preferred example wherein "R1" represents "heterocyclyl" is mono- or di-substituted heterocyclyl; wherein the heterocyclyl is pyrimidyl (especially pyrimidin-2-yl); wherein the substituents are independently selected from (Ci_4)alkyl, (Ci_4)alkoxy, halogen, trifluoromethyl and 15 -NR2R3. Especially, said pyrimidinyl is mono-substituted with halogen. A particular example is 5-bromo-pyrimidin-2-yl.
In case R1 is different from "heterocyclyl", it presents a lH-indenyl, a 2,3-dihydro-benzofuranyl-, a benzo[l,3]dioxolyl-, a 2,3-dihydro-benzo[l,4]dioxinyl-, a 4 H-benzo[l,3]dioxinyl-, a 2//-chromcnyl-, a chromanyl-, a 2,3-dihydro-thieno[3,4-20 b][l,4]dioxinyl-, a 3,4-dihydro-2//-benzo[l,4]oxazinyl- or a 2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuranyl-group. Especially it presents a 2,3-dihydro-benzo[l,4]dioxinyl-, a 2,3-dihydro-thieno[3,4-b][l,4]dioxinyl-, a 3,4-dihydro-2//-benzo[l,4]oxazinyl- or a 2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuranyl-group. The above-mentioned groups as used for the substituent R1 are unsubstituted or mono- or di-substituted wherein the substituents are / / Received at IPONZ on 20-Mar-2012 13 independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen. Preferably the above-mentioned groups are unsubstituted or mono-substituted with (Ci_4)alkyl. In particular, in case R1 is different from "heterocyclyl", the above mentioned groups as used for the substituent "R1" are preferably substituted as follows: 5 4//-benzo[l,3]dioxinyl-groups (especially 4//-bcnzo[ 1,3]dioxin-8-y1 or 4 H-benzo[l,3]dioxin-5-yl) are preferably unsubstituted, or mono-substituted in position 6 with fluoro; 3,4-dihydro-2//-bcnzo[ 1,4]oxaziny1-groups (especially 3,4-dihydro-2//-benzo[l,4]oxazin-5-yl) are preferably unsubstituted, or mono-substituted on the nitrogen atom with methyl (especially preferred: unsubstituted); 2,3-dihydro-benzofuranyl-groups 10 (especially 2,3-dihydro-benzofuran-4-yl (preferred) or 2,3-dihydro-benzofuran-7-yl), benzo[l,3]dioxolyl-groups (especially benzo[l,3]dioxol-4-yl), 2,3-dihydro-benzo[l,4]dioxinyl- (especially 2,3-dihydro-benzo[l,4]dioxin-5-yl), 2//-chromcnyl (especially chromen-5-yl), chromanyl- (especially chroman-5-yl or chroman-8-yl), 2,3-dihydro-thieno[3,4-b][l,4] dioxinyl- (especially 2,3-dihydro-thieno[3,4-b][l,4]dioxin-5-15 yl), and 2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuranyl-groups (especially 2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuran-4-yl) are preferably unsubstituted.
The term "NR2R3" as used for formula (I) means for example NH2 and N(CH3)2, NH(CH3), N(CH2CH3)2, NH(CH2CH3), N(CH3)(CH2CH3), and 1-pyrrolidino (especially it means NH2 and N(CH3)2).
The term "NR2R3" as used for formula (Ip) means for example NH2 and N(CH3)2.
The term "NR4R5" means for example NH2 and N(CH3)2.
The term "-NHS02-(Ci_4)alkyl" means for example -NHS02-CH3.
The term "-N(R4)C(0)R5" means for example the group -NHC(0)CH3.
The term "(Ci.4)alkoxy-(Ci_4)alkoxy" means for example the group CH3-0-CH2-CH2-0-. 25 Further embodiments of the invention are presented hereinafter: 3) A further embodiment of the invention relates to compounds according to embodiments 1) or 2), wherein n represents the integer 1. 4) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 3), wherein Received at IPONZ on 20-Mar-2012 14 A represents phenyl or 5- to 6-membered monocyclic heterocyclyl, wherein the phenyl or heterocyclyl is unsubstituted or independently mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (C3.6)cycloalkyl, (Ci_4)alkoxy, NR2R3 and halogen. 5) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 4), wherein B represents aryl, wherein the aryl is unsubstituted or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl and halogen. 6) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 5), wherein R1 represents heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen; or 15 R1 represents a lH-indenyl, a 2,3-dihydro-benzo[l,4]dioxinyl-, a 2,3-dihydro-thieno[3,4-b] [l,4]dioxinyl-, a 3,4-dihydro-2//-benzo[l,4]oxazinyl- or a 2,3,6,7-tetrahydro-benzo[l,2-b; 4,5-b']difuranyl-group, wherein said groups are unsubstituted or mono- or di-substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen. 7) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), wherein R1 represents heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen. 8) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7), wherein A represents 5- to 6-membered monocyclic heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-substituted wherein the substituent is selected from the group consisting of (Ci_4)alkyl, (C3.6)cycloalkyl and NR2R3. 9) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7), wherein, Received at IPONZ on 20-Mar-2012 in case R1 represents heterocyclyl, said heterocyclyl is selected from isoxazolyl, thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, pyrrolo[2,l-b]thiazolyl, imidazo[l,2-a]pyridyl and 5 imidazo[2,l-b]thiazolyl, wherein said heterocyclyl is unsubstituted or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci_4)alkoxy and halogen.
) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7), wherein, in case R1 represents heterocyclyl, said heterocyclyl is selected from thiazolyl, pyrazolyl, pyridyl, pyrimidyl, indolyl, benzofuranyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, quinolinyl, pyrrolo[2,l-b]thiazolyl, imidazo[l,2-a]pyridyl and imidazo[2,l-b]thiazolyl, wherein said heterocyclyl is unsubstituted or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group 15 consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen. 11) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7) or 9) to 10), wherein A represents an oxazolyl-, a thiazolyl-, a pyrimidinyl-, a thiophenyl-, a pyrimidinyl-, or a pyrazinyl-group (notably an oxazolyl-, a thiazolyl-, or a pyrimidinyl-group), wherein said 20 group is unsubstituted or mono-substituted, wherein the substituent is selected from (Ci_ 4)alkyl, (C3.6)cycloalkyl, (Ci_4)alkoxy and NR2R3. 12) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 11), wherein A represents a thiazolyl-group, wherein said group is unsubstituted or mono-substituted, 25 wherein the substituent is selected from (Ci_4)alkyl, (C3.6)cycloalkyl and NR2R3. 13) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7), 9) or 10), wherein A represents a phenyl-group, wherein said group is unsubstituted or mono-substituted with (Ci_4)alkyl. 14) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7), 9) or 10), wherein A represents an unsubstituted phenyl-group.
Received at IPONZ on 20-Mar-2012 16 ) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 11), wherein A represents a pyrimidyl-group, wherein said group is mono-substituted with (Ci_4)alkyl. 16) A further embodiment of the invention relates to compounds according to any one of 5 embodiments 1) to 11), wherein A represents an unsubstituted pyrazinyl-group. 17) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 11), wherein A represents an unsubstituted thiophenyl-group. 18) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 11), wherein A represents an oxazolyl-group, wherein said group is mono-substituted with (Ci_4)alkyl. 19) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 3), 4), or 6) to 19), wherein B represents phenyl, wherein the phenyl is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of 15 (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy and halogen.
) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 19), wherein B represents phenyl, wherein the phenyl is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of 20 (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl and halogen. 21) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 8) or 11) to 20), wherein R1 represents a lH-indenyl, a 2,3-dihydro-benzo[l,4]dioxinyl-, a 2,3-dihydro-thieno[3,4-b] [l,4]dioxinyl-, a 3,4-dihydro-2//-benzo[l,4]oxazinyl- or a 2,3,6,7-tetrahydro-benzo[l,2-b; 25 4,5-b']difuranyl-group wherein said groups are unsubstituted or mono- or di-substituted wherein the substituents are independently selected from the group consisting of (Ci_4) alkyl, (Ci_4)alkoxy and halogen. 22) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 8) or 11) to 20), wherein Received at IPONZ on 20-Mar-2012 17 R1 represents a 2,3-dihydro-benzo[l,4]dioxinyl-, a 2,3-dihydro-thieno[3,4-b][l,4]dioxinyl-, a 3,4-dihydro-2//-benzo[ 1,4]oxazinyi- or a 2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuranyl-group wherein said groups are unsubstituted. 23) A further embodiment of the invention relates to compounds according to any one of 5 embodiments 1) to 20), wherein, in case R1 represents heterocyclyl, said heterocyclyl is selected from pyrrolo[2,l-b] thiazolyl and imidazo[2,l-b]thiazolyl, wherein said heterocyclyl is unsubstituted or mono-substituted with (Ci_4)alkyl. 24) A further embodiment of the invention relates to compounds according to any one of 10 embodiments 1) to 20), wherein, in case R1 represents heterocyclyl, said heterocyclyl is pyrimidyl, which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from (Ci_4)alkyl, (Ci_4)alkoxy and halogen.
) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 20) or 24), wherein, in case R1 represents heterocyclyl, said heterocyclyl is pyrimidyl which is mono-substituted with halogen. 26) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 2), 4) to 20), or 24) to 25), wherein n represents the integer 0. 27) In another embodiment of the invention examples of compounds according to embodiment 1) are selected from the group consisting of: Quinoline-8-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Quinoline-8-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide;0 2,3-Dihydro-benzo[l,4]dioxine-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-25 methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 2,3-Dihydro-benzo[l,4]dioxine-5-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzofuran-4-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzofuran-4-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Received at IPONZ on 20-Mar-2012 18 Benzofuran-4-carboxylic acid [(lR,3S,4S)-2-(2-methyl-4-phenyl-pyrimidine-5-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(biphenyl-2-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-bromo-4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 2,3,6,7-Tetrahydro-benzo[l,2-b;4,5-b']difuran-4-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 1-Methyl-lH-benzoimidazole-2-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Received at IPONZ on 20-Mar-2012 19 1-Methyl-lH-indazole-3-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 2-Methyl-benzooxazole-4-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-pyrrolo[2,l-b]thiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 1-Methyl-lH-benzoimidazole-2-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-10 fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 R,3 S ,4S)-2- [2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 1,2-Dimethyl-1 H-indole-3 -carboxylic acid {(1 R,3 S ,4S)-2-[2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 15 5-Fluoro-l-methyl-lH-indole-2-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; and 2-Methyl-benzooxazole-4-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide. 28) In another embodiment, in addition to the compounds listed in embodiment 27), further 20 examples of compounds according to embodiment 1) are selected from the group consisting of: Benzothiazole-7-carboxylic acid {(R,S,S)-2-[5-(3-chloro-phenyl)-2-methoxy-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,S,S)-2-[5-(3-chloro-phenyl)-2-ethoxy-thiazole-4-25 carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,S,S)-2-[5-(3-chloro-phenyl)-2-(2-methoxy-ethoxy)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,S,S)-[2-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]}-amide; Benzothiazole-7-carboxylic acid {(R,R,S)-2-[2-cyclopropyl-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Received at IPONZ on 20-Mar-2012 Benzothiazole-7-carboxylic acid {(R,R,S)-2-[2-methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,R,S)-2-[2-dimethylamino-5-(3,4-dimethyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 5 Benzothiazole-7-carboxylic acid {(R,R,S)-2-[5-(3-chloro-phenyl)-2-dimethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,R,S)-2-[5-(3-chloro-phenyl)-2-(ethyl-methyl-amino)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-diethylamino-10 thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(3-p-tolyl-pyrazine-2-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(4-methoxy-phenyl)-thiophene-2-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(3-methoxy-phenyl)-thiophene-2-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(3,4-dimethoxy-phenyl)-thiophene-2-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide; Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(3-benzo[l,3]dioxol-5-yl-thiophene-2-20 carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(2-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 25 Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-cyclopropyl-5-p-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-cyclopropyl-5-(2-fluoro-phenyl)-3 0 thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide; Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-cyclopropyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Received at IPONZ on 20-Mar-2012 21 Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-cyclopropyl-5-(3-fluoro-4-methyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 5 Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-ethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 R,3 S ,4S)-2- [2-methyl-5 -(3 -trifluoromethoxy-phenyl)-oxazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzo[d]isothiazole-3-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-10 phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; -Ethyl-3-methyl-isoxazole-4-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 3-Ethyl-5-methyl-isoxazole-4-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 15 Quinoxaline-5-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 R,3 S ,4S)-2- [3 -(1 H-indol-6-yl)-pyrazine-2-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide; Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[5-(2-fluoro-phenyl)-2-pyrrolidin-l-yl-20 thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid [(1 S,3R,4R)-2-(2-dimethylamino-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-(ethyl-methyl-amino)-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 25 Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[5-(3-bromo-4-fluoro-phenyl)-2-dimethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[5-(4-fluoro-phenyl)-2-pyrrolidin-l-yl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-dimethylamino-5-(4-fluoro-phenyl)-3 0 thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide; Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-diethylamino-5-(2-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Received at IPONZ on 20-Mar-2012 22 Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-dimethylamino-5-(3-fluoro-4-methyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-(ethyl-methyl-amino)-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 5 Benzothiazole-7-carboxylic acid [(lS,3R,4R)-2-(2-dimethylamino-5-p-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-dimethylamino-5-(3-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; and Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-diethylamino-5-(4-fluoro-phenyl)-10 thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide.
Also part of the invention are compounds of formula (I) and pharmaceutically acceptable salts thereof.
The term "pharmaceutically acceptable salts" refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. 15 Pharm. (1986), 33, 201-217.
Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases or the like, this is intended to mean also a single compound, salt, disease or the like.
The compounds of formula (I) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parenteral 20 administration.
A further aspect of the invention is a pharmaceutical composition containing at least one compound according to formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier material.
The production of the pharmaceutical compositions can be effected in a manner which will 25 be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of Formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with 30 suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
Received at IPONZ on 20-Mar-2012 23 A further aspect of the invention is a use of a compound of the invention or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use and abuse, of 5 cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.
Described herein is a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I).
The compounds according to formula (I) may be used for the preparation of a medicament and are suitable for the prevention or treatment of diseases selected from the group consisting of dysthymic disorders including major depression and cyclothymia, affective neurosis, all types of manic depressive disorders, delirium, psychotic disorders, schizophrenia, catatonic schizophrenia, delusional paranoia, adjustment disorders and all 15 clusters of personality disorders; schizoaffective disorders; anxiety disorders including generalized anxiety, obsessive compulsive disorder, posttraumatic stress disorder, panic attacks, all types of phobic anxiety and avoidance; separation anxiety; all psychoactive substance use, abuse, seeking and reinstatement; all types of psychological or physical addictions, dissociative disorders including multiple personality syndromes and 20 psychogenic amnesias; sexual and reproductive dysfunction; psychosexual dysfunction and addiction; tolerance to narcotics or withdrawal from narcotics; increased anaesthetic risk, anaesthetic responsiveness; hypothalamic-adrenal dysfunctions; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders including neuropathic pain and restless leg syndrome; sleep apnea; narcolepsy; 25 chronic fatigue syndrome; insomnias related to psychiatric disorders; all types of idiopathic insomnias and parasomnias; sleep-wake schedule disorders including jet-lag; all dementias and cognitive dysfunctions in the healthy population and in psychiatric and neurological disorders; mental dysfunctions of aging; all types of amnesia; severe mental retardation; dyskinesias and muscular diseases; muscle spasticity, tremors, movement disorders; 30 spontaneous and medication-induced dyskinesias; neurodegenerative disorders including Huntington's, Creutzfeld-Jacob's, Alzheimer's diseases and Tourette syndrome; Amyotrophic lateral sclerosis; Parkinson's disease; Cushing's syndrome; traumatic lesions; Received at IPONZ on 20-Mar-2012 24 spinal cord trauma; head trauma; perinatal hypoxia; hearing loss; tinnitus; demyelinating diseases; spinal and cranial nerve diseases; ocular damage; retinopathy; epilepsy; seizure disorders; absence seizures, complex partial and generalized seizures; Lennox-Gastaut syndrome; migraine and headache; pain disorders; anaesthesia and analgesia; enhanced or 5 exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; dental pain; pain related to infection e.g. by HIV; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; osteoarthritis; conditions associated with visceral pain such as irritable bowel syndrome; 10 eating disorders; diabetes; toxic and dysmetabolic disorders including cerebral anoxia, diabetic neuropathies and alcoholism; appetite, taste, eating, or drinking disorders; somatoform disorders including hypochondriasis; vomiting/nausea; emesis; gastric dyskinesia; gastric ulcers; Kallman's syndrome (anosmia); impaired glucose tolerance; intestinal motility dyskinesias; hypothalamic diseases; hypophysis diseases; hyperthermia 15 syndromes, pyrexia, febrile seizures, idiopathic growth deficiency; dwarfism; gigantism; acromegaly; basophil adenoma; prolactinoma; hyperprolactinemia; brain tumors, adenomas; benign prostatic hypertrophy, prostate cancer; endometrial, breast, colon cancer; all types of testicular dysfunctions, fertility control; reproductive hormone abnormalities; hot flashes; hypothalamic hypogonadism, functional or psychogenic 20 amenorrhea; urinary bladder incontinence; asthma; allergies; all types of dermatitis, acne and cysts, sebaceous gland dysfunctions; cardiovascular disorders; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; dyslipidemias, hyperlipidemias, insulin resistance; urinary retention; osteoporosis; angina pectoris; myocardial infarction; arrhythmias, coronary diseases, left ventricular hypertrophy; 25 ischemic or haemorrhagic stroke; all types of cerebrovascular disorders including subarachnoid haemorrhage, ischemic and hemorrhagic stroke and vascular dementia; chronic renal failure and other renal diseases; gout; kidney cancer; urinary incontinence; and other diseases related to general orexin system dysfunctions.
Compounds of formula (I) are particularly suitable for use in the treatment of diseases or 30 disorders selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use and abuse, of cognitive dysfunctions in the Received at IPONZ on 20-Mar-2012 healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.
Eating disorders may be defined as comprising metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa. Pathologically 5 modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs. expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance. Drinking disorders include polydipsias in psychiatric disorders and all other types of excessive fluid intake. Sleep disorders include 10 all types of parasomnias, insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders. Insomnias are defined as comprising sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new 15 environment, noise) or short-term insomnia due to stress; grief; pain or illness. Insomnia also include stress-related syndromes including post-traumatic stress disorders as well as other types and subtypes of anxiety disorders such as generalized anxiety, obsessive compulsive disorder, panic attacks and all types of phobic anxiety and avoidance; psychoactive substance use, abuse, seeking and reinstatement are defined as all types of 20 psychological or physical addictions and their related tolerance and dependence components. Cognitive dysfunctions include deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
In a further preferred embodiment of the invention compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of sleep disorders that comprises all types of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase 30 syndrome or insomnias related to psychiatric disorders.
In another preferred embodiment of the invention compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the Received at IPONZ on 20-Mar-2012 26 group consisting of cognitive dysfunctions that comprise deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
In another preferred embodiment of the invention compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of eating disorders that comprise metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa.
In another preferred embodiment of the invention compounds of formula (I) are 10 particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of psychoactive substance use and abuse that comprise all types of psychological or physical addictions and their related tolerance and dependence components.
Besides, any preferences indicated for the compounds of formula (I) (whether for the 15 compounds themselves, salts thereof, compositions containing the compounds or salts thereof, uses of the compounds or salts thereof, etc.) apply mutatis mutandis to compounds of formula (IP).
Also described herein is a process for the preparation of compounds of formula (I). Compounds according to formula (I) of the present invention can be prepared according to 20 the general sequence of reactions outlined in the schemes below, wherein A, B, n and R1 are as defined for formula (I). The compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se.
In general, all chemical transformations can be performed according to well-known standard methodologies as described in the literature or as described in the procedures 25 below.
The term "comprising" as used in this specification and claims means "consisting at least in part of'. When interpreting statements in this specification and claims which includes the "comprising", other features besides the features prefaced by this term in each statement can also be present. Related terms such as "comprise" and "comprised" are to be 30 interpreted in similar manner.
Received at IPONZ on 20-Mar-2012 27 In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such 5 documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.
In the description in this specification reference may be made to subject matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the 10 invention as defined in the claims of this application.
Preparation of compounds of formula (I): (1S ,3 S,4R)-2-((R)-1 -Phenyl-ethyl)-2-aza-bicyclo[2.2.1 ]hept-5 -ene-3 -carboxylic acid methyl ester (1) can be synthesized according to a literature procedure (N. Hashimoto, H. 15 Yasuda, M. Hayashi, Y. Tanabe Org. Proc. Res. Dev., 2005, 9, 105-109); the configuration of the stereocenters is assigned in accordance with this reference as well. The exchange of the protecting group to tert-butoxy-carbonyl can be done by removal of the phenethyl-moiety of (1) under hydrogenation conditions (e.g. H2 and catalytic amounts of Pd/C) in the presence of B0C2O. By reduction of the ester-functionality of (2) with, for instance, 20 DIBAL at low temperatures the respective alcohol (3) can be obtained which can be oxidized to aldehyde (4) by Swern- or Dess-Martin-oxidation. After reductive amination of (4) with benzylamine in the presence of a reducing agent like sodium triacetoxyborohydride the benzyl group of (5) can be removed by hydrogenolysis to yield the primary amine (6). The acylation of (6) with a carboxylic acid R'COOH in the 25 presence of a coupling reagent like TBTU resulted in the formation of amides (7) which after removal of the Boc-group under acidic conditions (e.g. HC1 in dioxane) can be transferred to compounds of formula (I) by amide coupling (e.g. B-A-COOH, TBTU or B-A-COC1).
Received at IPONZ on 20-Mar-2012 28 (R) O rs; N rs; H2i Pd/C /^Ph 1 B0C2O (S) O K(S) (R) N Boc O" DIBAL THF, -78^0 OH N Boc (C0CI)2 DMSO, NEt3 DCM, -60'C O N Boc PhCH2NH2 NaBH(0Ac)3 DCM N Ph N H Boc H2, Pd/C EtOH nh2 N Boc R1C00H TBTU O nV N H Boc 1) HCI, dioxane 2) B-A-COOH TBTU or B-A-COCI O hnar1 (R) N rs; \ B 8 Scheme 1: Synthesis of compounds of formula (I) Another approach to compounds of formula (I) may start with the protection of amine (6) with ethyl trifluoroacetate in the presence of a base like DIPEA to give amides (9) which can be Boc-deprotected with an acid like HCI in a solvent like dioxane {Scheme 2). The obtained amine (10) can be coupled with a carboxylic acid B-A-COOH in the presence of a coupling reagent like TBTU or with an acid chloride B-A-COCI to an amide (11). After deprotection with for instance K2C03 or NaOH in alcohol/water mixtures amines (12) can be obtained which can be coupled with a carboxylic acid R'COOH in the presence of a coupling reagent like TBTU to compounds (8) of formula (I).
Received at IPONZ on 20-Mar-2012 29 (R) >h2 F-i' N DIPEA Boc 6 THF O B-A-COOH n\)F3 TBTU , H or B-A-COCI N ~N^CF3 k2co3 x^° \ 11 B 11 H20 / MeOH 6CTC N ~NHo 1 2 R COOH \ 12 B TBTU Scheme 2: Alternative synthesis of compounds of formula (I) O hnar1 (R) N rs; J=° B rs; rs; NH; R1-X (R) N Boc 6 k2co3 DIPEA xylene, A R1-X K2C03 DIPEA xylene, A Scheme 3: Alternative synthesis of compounds of formula (I), wherein n equals 0; X represents chlorine or bromine Compounds of formula (I) in which n equals 0 can be synthesized according to one of the pathways described in scheme 3. Starting from the Boc-protected compound (6) heterocyclyl-substituted compounds (13) may be obtained in a substitution reaction with for instance heterocyclyl chlorides or bromides in the presence of a base like K2CO3 and/or DIPEA at elevated temperatures. After acid catalyzed removal of the Boc-protecting group compounds (14) of formula (I) can be obtained by amide coupling with the respective carboxylic acid B-A-COOH in the presence of a coupling reagent like for instance TBTU or by reaction with an acid chloride like B-A-COCI in the presence of a base like DIPEA.
Received at IPONZ on 20-Mar-2012 Alternatively compounds (12) may be transferred to compounds (14) of formula (I) by substitution reaction with for instance heterocyclyl chlorides or bromides in the presence of a base like K2CO3 and/or DIPEA at elevated temperatures.
Thiazole-4-carboxylic acid derivatives of formula B-A-COOH can for instance be synthesised according to scheme 4.
CI O O" CI 15 B CHO CI O KOf-Bu THF B Y u o 16 s ranh2 OH" N^COOMe R-C Jf s B [R = (C1_4)alkyl, (C3-6)cycloalkyl, n^cooh r^T sab 17 NR2R3] 18 CuBr2, MeCN isoamylnitrite (R = NH2) 1) r2r3nh N^COOMe Br^'I S B 2) OH r2 n COOH 1) NaOR' [R* = (C1_4)alkyl] 2) NaOH 19 r3 s b Pd/C, H2 EtOH R'\ NrC00H chl! S B N COOMe OH" Aldehydes B-CHO are commercially available or may be synthesized by procedures known from the literature like for instance reduction of the respective carboxylic acid or 15 their different derivatives with a reducing agent, by reduction of the respective nitrile or by oxidation of benzylic alcohols and their heterocyclic analogues with oxidating agents (e.g.: J. March, Advanced Organic Chemistry, 4th edition, John Wiley & Sons, p. 447-449, 919-920 and 1167-1171).
(C3-6)Cycloalkyl-thioamides may be synthesized by treatment of (C3-6)cycloalkyl-20 carboxamides with Lawesson's reagent.
Carboxylic acids of formula R'-COOH are commercially available or well known in the art (Lit. e.g. W02001/96302; T. Eicher, S. Hauptmann "The chemistry of Heterocycles: Structure, Reactions, Syntheses, and Applications", 2nd Edition 2003, Wiley, ISBN 978-3-527-30720-3).
Derivatives of formula R^COOH wherein R1 is benzo[l,4]oxazine can be synthesised according to scheme 5.
By hydrogenation of methyl 3-nitrosalicylate (commercially available) in MeOH 3-amino-2-hydroxy-benzoic acid methyl ester (26, Ra = COOMe, Rb = H) may be obtained. The regioisomer (26, Ra = H, Rb = COOMe) may be synthesized by esterification of 30 commercially available 3-hydroxyanthranilic acid with (trimethylsilyl)diazomethane. Cyclization of one or the other amino-hydroxy-benzoic acid (26) with chloroacetyl Received at IPONZ on 20-Mar-2012 32 chloride in the presence of a base like k2co3 may lead to 3-oxo-3,4-dihydro-2H-benzo[l,4]oxazine derivatives (27) which may be reduced to 3,4-dihydro-2H-benzo[l,4]oxazine derivatives (28) with NaBH4 in the presence of boron trifluoride diethyl etherate. Compounds (28) may be alkylated at the nitrogen atom with methyl iodide in the presence of a base like k2co3 in a solvent like DMF to give the respective analogues (29). By saponification of the respective ester derivatives (28 or 29) with NaOH in a solvent mixture like water/EtOH the desired acids (30, 31, 32 or 33) may be obtained. ^_OH CO^/le NH2 C02H 25 (CH3)3SiCHN2 MeOH, toluene O Clx_AC| K2C03, DMF yPN O R H R (V\ rTN( 27 Ra = C02Me, R = H or BF3OEt2 NaBH4, THF Ra = H, R° = C02Me Mel K2C03, DMF Ester cleavage: NaOH EtOH / H20 : R = H, Rc = COOH, R = H 31: R = H, Rc = H, Rd = COOH 32: R 33: R Me, R Me, Ru = H, R COOH, R d H COOH 28 or 29 Scheme 5: Synthesis of benzo[l,4]oxazine-carboxylic acid derivatives Derivatives of formula R'-COOH wherein R1 is chroman may be for instance synthesised according to scheme 6.
The synthesis of chroman-5-carboxylic acid derivatives may be started with the alkylation of 3-hydroxy-benzoic acid methyl ester (34; commercially available) with propargyl bromide in the presence of K2C03 to give phenylether (35) which may be cyclised to the chromen derivative (36) by heating to reflux in N,N-diethylaniline. The carboxylic ester Received at IPONZ on 20-Mar-2012 33 may be saponified by treatment of (36) with NaOH in MeOH and water and the obtained chromen derivative (37) may be hydrogenated to give the desired acid (38). The corresponding chroman-8-carboxylic acid derivatives may be synthesized by reduction of 4-chromanone (39; commercially available) with zinc in acetic acid and subsequent ortho-metalation of the intermediate chroman derivative (40) with n-BuLi and trapping with carbon dioxide to give the desired acid (41).
C02CH3 ^ co2ch3 co2ch3 L 1 OH k2co3 ^^0"N^ PhNEt2 34 DMF 35 A. 15 h 36 C02H NaOH H2 ch3oh, H20^0^ Pd/C 37 n ^ C°2H cy CO eo O 39 40 41 Scheme 6: Synthesis of chroman-carboxylic acid derivatives Derivatives of formula R'-COOH wherein R1 is imidazo[2,l-b]thiazole may be for instance synthesised according to one of the different pathways shown in scheme 7.
Following pathway A imidazo[2,l-b]thiazole-carboxylic acid derivatives may be synthesized starting from 2-chloro-3-oxo-butyric acid methyl ester (42; commercially available) by reaction with thiourea in a solvent like EtOH at elevated temperatures. The obtained amino-thiazole (43) may be converted to the imidazo[2,l-b]thiazole derivative (44) by alkylation and subsequent cyclization with bromoacetaldehyde diethyl acetal in the presence of an acid like concentrated hydrochloric acid. By saponification of (44) with for instance NaOH in solvents like THF and MeOH the desired acids (45) may be obtained.
Received at IPONZ on 20-Mar-2012 34 Pathway A 9 9 H2NANH2 "YVNH, BI"^OBI CMKS OH" [JVS 6, °" "W Vs"" hc ■ NrV°^ " NrV°H 42 43 44 45 Pathway B R a H Rr^^OR H pn r -N QR \y--N HCI 2 V"^v T -)-S OR nui . JLXS RO^AN Na0Et ROV-N w O H EtOH O ra 0r ho r° 46 47 48 POCh R°2CVN. OH" H°2CYN Ks - N r /~N " Ra 49 50 Pathway C OMe Da k, N^OMe Da n —d" r n_,N l R %--N O da h Br -N^OMs .. Br^YOEt Et02C^ JIN I ' x \^IN KJ D* Ji s) nh2 ^ Jf /^Nx / M K~ S toluene Rb N bXs^" ^N K \ 51 52 53 rN rN DBU XN?^S OH" Lh? Et02C' H02C N DMF " Rfl' Rb Ra Rb 54 55 Pathway D O Br^^CF3 F3C n poci3 F3C n NaCI02 F3C N f >-NH2 T vs T vs T vo S acetone N^j DMF OHC NaH2P04 HO^/^n^j O 56 57 58 59 Scheme 7: Synthesis of imidazo[2,l-b]thiazole-carboxylic acid derivatives wherein R is 10 methyl or ethyl, Ra is hydrogen or methyl, Rb is hydrogen or methyl Received at IPONZ on 20-Mar-2012 Alternatively (pathway B) the imidazole derivative (46) may be transferred to the acetal (47) by alkylation with a bromoacetaldehyde dialkyl acetal derivative in the presence of a base like sodium ethoxide. Cyclization under acidic conditions (e.g. aq. hydrochloric acid) and dehydration of the intermediate (48) with for instance phosphorus oxychloride may lead to ester (49) which may be transformed to the desired acid (50) by saponification with for instance NaOH in solvents like THF and MeOH.
In still an alternative procedure (pathway C) the respective amino-thiazole (51; commercially available) may be converted to the formamidine derivative (52) by heating (51) with /V, /V-di mcth y 1 form am i dc dimethylacetale in a solvent like toluene. After alkylation with ethyl bromoacetate the respective thiazolium bromide (53) may be cyclised with DBU to yield the ester (54) which may be saponified to the desired acid (55) with for instance NaOH in solvents like THF and MeOH.
Finally pathway D may start with the alkylation of 2-amino-thiazole with 3-bromo-l,l,l-trifluoroacetone to yield the trifluoromethyl-substituted imidazo[2,l-b]thiazole derivative (57) which may be formylated to the aldehyde (58) by reaction with phosphorus oxychloride in a solvent like DMF. By oxidation of aldehyde (58) with sodium chlorite the desired imidazo[2,l-b]thiazole-carboxylic acid (59) may be obtained. In analogy, the commercially available chlorinated aldehyde (58, being substituted with CI instead of CF3) may be oxidized to the corresponding acid.
Derivatives of formula R'-COOH wherein R1 is pyrrolo[2,l-b]thiazole were for instance synthesised according to the pathway shown in scheme 8. tms tms ®j tfn 0 ^cooet C02Et 60 NBS Br C02Et 1) Me2Zn, 62 4 dioxane, A co2h DCM ~NsJ? 2) NaOH 61 63 Scheme 8: Synthesis of pyrrolo[2,l-b]thiazole-carboxylic acid derivatives Received at IPONZ on 20-Mar-2012 36 By reaction of 2-methylsulfanylthiazole with trimethylsilylmethyl trifluoromethanesulfonate followed by cyclisation of the resulting thiazolinium salt by reaction with ethyl propiolate in the presence of CsF, the pyrrolo[2,l-Z>]thiazole (60) can be obtained (Berry C.R. et al., Organic Letters, 2007, 9, 21, 4099-4102). Ester (61) was 5 obtained by bromination of pyrrolo[2,l-b]thiazole-7-carboxylic acid ethyl ester (60) with NBS. In a Negishi-type coupling of (61) with dimethylzinc in the presence of catalytic amounts of [l,l'-Bis(diphenylphosphino) ferrocene]dichloropalladium(II) (62) the bromine atom was replaced by a methyl group to give after saponification with a base like NaOH in a solvent mixture like EtOH/water the acid derivative (63).
Derivatives of formula R'-COOH wherein R1 is benzothiazole were for instance synthesised according to the pathway shown in scheme 9.
C02Me C02Me C02Me KSCN A S Br2 /CS ^NH2 crown ether XAnANH2 HQAc! 0tc H+ H 64 65 66 C02Me C02H ^2 JCs Na0H Xs reflux H20, MeOH ^^isf THF 67 68 Scheme 9: Synthesis of benzothiazole-carboxylic acid derivatives By reaction of 3-amino-benzoic acid methyl ester (64) with potassium thiocyanate the 15 respective thiourea derivative (65) is obtained which can be cyclised by treatment with an oxidizing reagent like bromine in an acid like acetic acid to 2-amino-benzothiazole derivatives (66). The amino group can be removed with, for instance, isoamyl nitrite to give ester derivatives (67) which can be saponified to acid derivatives (68) with a base like NaOH in solvents or mixtures of solvents like water, MeOH and THF.
Derivatives of formula R'-COOH wherein R1 is benzoxazole can be synthesised according to one of the pathways shown in scheme 10.
By reaction of 3-aminosalicylic acid (69) with the respective ortho-ester derivative the desired benzoxazole-7-carboxylic acid derivatives (70) can be obtained. The reaction may be catalyzed by addition of an acid like PTSA. The respective benzoxazole-4-carboxylic Received at IPONZ on 20-Mar-2012 37 acid derivatives (72) can be synthesized by reaction of 2-amino-3-hydroxy-benzoic acid ethyl ester [(71), J. Reisch, G. M. K. B. Gunaherath Monatshefte fur Chemie, 1988, 119, 1169-1178] with acetyl chloride in the presence of TEA and PPTS at elevated temperatures and subsequent saponification of the obtained ester with a base like potassium hydroxide in a solvent mixture like MeOH/water.
C02H OH NH5 69 RaC(OR)3 C02H O />—Rc N 70 C02Et NH2 OH 71 1) CH3COCI NEt3, PPTS 2) KOH C02H N \V o 72 Scheme 10: Synthesis of benzoxazole-carboxylic acid derivatives wherein R is methyl or ethyl and Ra is hydrogen or methyl B NaNO; O O bVo- o o o I HgCI2, Zn B OH HN 73 O 11 crs"ci 74 75 NaOH 76 77 Scheme 11: Synthesis of oxazole-4-carboxylic acid derivatives, wherein R is methyl.
By reaction of a commercially available 3-oxo-propionic acid ester derivative 73 with an aq. solution sodium nitrite in presence of an acid such as glacial acetic acid the corresponding oxime derivative 74 can be obtained. The 2-acetamido-3-oxo-propionic acid ester derivative 75 can be synthesized from compounds of structure 74 using acetic anhydride in presence of an acid such as glacial acetic acid and catalytic amounts of metal chlorides such as mercury chloride and zinc powder. Cyclization to the corresponding corresponding oxazole-4 carboxylic acid ester derivative 76 can be achieved under Received at IPONZ on 20-Mar-2012 38 dehydrating conditions such as SOCl2 in CHC13. Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in solvent mixtures such as EtOH/water provides the corresponding oxazole-4 carboxylic acid derivative 77.
O O "OH B-B(OH)2 /S^ "OH 78 K2CO3 (2M) i-PrOH / Toluene Pd(PPh3)4 79 Scheme 12: Synthesis of thiophene-2-carboxylic acid derivatives.
Suzuki-reaction under standard conditions of commercially available 3-bromo-thiophene-2-carboxylic acid (78) with commercially available aryl-boronic acids provides the corresponding 3-aryl-thiophene-2-carboxylic acid derivative 79.
N. N 80 CN CI B-B(OH)2 ► K2CO3 (2M) i-PrOH / Toluene Pd(PPh3)4 N N 81 CN B NaOH MeOH N.
N 82 COOH B Scheme 13: Synthesis of 3-aryl-pyrazine-2-carboxylic acid derivatives.
Suzuki-reaction under standard conditions of commercially available 3-chloro-pyrazine-2-carbonitrile (80) with commercially available aryl-boronic acids provides the corresponding 3-aryl-pyrazine-2-carbonitrile derivative 81 which is transformed to the desired carboxylic acid derivative 82 by hydrolysis of the nitrile under basic conditions in a 15 solvent like MeOH.
R -NH2 CH3CN, NEt3 rt to SO'C 83 84 Scheme 14: Alternative synthesis of final compounds with monoalkyl-amino-substituents in position 2 of the 5-arylthiazole substituent.
Received at IPONZ on 20-Mar-2012 39 The 2-bromo-5-arylthiazole containing precursor 83 (prepared according to procedures given within this application) can be treated in a solvent like acetonitrile with an aq. solution of the respective primary amine to yield compounds 84.
Whenever the compounds of formula (I) are obtained in the form of mixtures of 5 enantiomers, the enantiomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Regis Whelk-01(R,R) (10 jjrn) column, a Daicel ChiralCel OD-H (5-10 jj,m) column, or a Daicel ChiralPak IA (10 jjrn) or AD-H (5 jjrn) column. Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or 10 absence of an amine such as TEA, diethylamine) and eluent B (hexane), at a flow rate of 0.8 to 150 mL/min.
Experimental Section 15 Abbrevations (as used herein and in the description before): aq aqueous Boc fer/-Butoxy carb onyl BSA Bovine serum albumine CHO Chinese hamster ovary conc.
Concentrated d Day(s) DBU l,8-Diazabicyclo[5.4.0]undec-7-ene DCM Dichloromethane DIBAL Diisobutylaluminium hydride DIPEA Diisopropylethylamine DMAP 4-Dimethylaminopyridine DMF N, /V- Di m ethyl form am i dc DMSO Dimethylsulfoxide eq Equivalent(s) ES Electron spray ether Diethylether Received at IPONZ on 20-Mar-2012 40 EtOAc Ethyl acetate EtOH ethanol FCS Foatal calf serum FLIPR Fluorescent imaging plate reader h Hour(s) HBSS Hank's balanced salt solution HEPES 4-(2-hydroxyethyl)-piperazine-l-ethanesulfonic acid HPLC High performance liquid chromatography LC Liquid chromatography M Molar(ity) MeCN Acetonitrile MeOH Methanol min Minute(s) MS Mass spectroscopy NBS A - B rom os uc c i n i m i dc PPTS Pyridinium para-to) ucn cs ul fon ate prep. Preparative PTSA para-Tol ucn cs ul fon i c acid monohydrate rt Room temperature sat Saturated tR Retention time TBME tert-Butyl methyl ether TBTU O-Benzotriazol-l-yl-Af AfiV^iV'-tetramethyluronium tetrafluoroborate TEA Triethylamine TFA Trifluoroacetic acid TFAA Trifluoroacetic anhydride THF Tetrahydrofuran I-Chemistry The following examples illustrate the preparation of pharmacologically active compounds of the invention but do not at all limit the scope thereof.
All temperatures are stated in °C.
Received at IPONZ on 20-Mar-2012 41 Compounds are characterized by: ^-NMR: 300 MHz Varian Oxford or 400 MHz Bruker Avance; chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = broad, coupling constants are given in Hz; LC-MS: Agilent 1100 series with DAD and MS detection (MS: Finnigan single quadrupole); columns (4.6x50 mm, 5 jj,m): Zorbax SB-AQ, Zorbax Extend C18 or Waters XBridge CI8; conditions (if not otherwise stated the acidic gradient is used): 10 basic: eluent A: MeCN, eluent B: conc. NH3 in water (1.0 mL/L), 5% to 95% CH3CN, flow rate 4.5 mL/min; acidic: eluent A: MeCN, eluent B: TFA in water (0.4 mL/L), 5% to 95% CH3CN, flow rate 4.5 mL/min; tR is given in min; In case of a partial separation of rotamers, as seen for several examples of compounds of formula (I), two retention times are given.
Compounds are purified by column chromatography on silica gel or by preparative HPLC using RP-Cis based columns with MeCN/water gradients and formic acid or ammonia additives.
A. Preparation of building blocks: A.l Synthesis of thiazole-4-carboxylic acid derivatives A. 1.1 Synthesis of 3-chloro-2-oxo-propionic ester derivatives (general procedure) CI o A solution of the respective aldehyde (338 mmol, 1.0 eq) and methyl dichloroacetate (338 mmol, 1.0 eq) in THF (100 mL) is added dropwise to a cold (-60°C) suspension of KOtBu (335 mmol, 1.0 eq) in THF (420 mL). After 4 h the mixture is allowed to reach rt, stirred over night and concentrated in vacuo. DCM and ice-cold water are added, the layers are separated and the aq. layer is extracted twice with DCM. The combined organic layers are 30 washed with ice-cold water and brine, dried over MgS04 and concentrated in vacuo to give Received at IPONZ on 20-Mar-2012 42 the desired 3-chloro-2-oxo-propionic ester derivative which is used without further purification. 3-Chloro-2-oxo-3-m-tolyl-propionic acid methyl ester prepared by reaction of 3-methyl-benzaldehyde with methyl dichloroacetate. 3-Chloro-2-oxo-3-p-tolyl-propionic acid methyl ester prepared by reaction of 4-methyl-benzaldehyde with methyl dichloroacetate. 3-Chloro-3-(3-methoxy-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3-methoxy-benzaldehyde with methyl dichloro-acetate. 3-Chloro-3-(2-fluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 2-fluoro-benzaldehyde with methyl dichloro-acetate. 3-Chloro-3-(3-fluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3-fluoro-benzaldehyde with methyl dichloroacetate. 3-Chloro-3-(4-fluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 4-fluoro-benzaldehyde with methyl dichloroacetate. 3-Chloro-3-(3-chloro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3-chloro-benzaldehyde with methyl dichloro-acetate. 3-Chloro-2-oxo-3-(3-trifluoromethyl-phenyl)-propionic acid methyl ester prepared by reaction of 3-trifluoromethyl-benzaldehyde with methyl dichloro-acetate. 3-Chloro-3-(3,4-dimethyl-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3,4-dimethyl-benzaldehyde with methyl dichloro-acetate. 3-Chloro-3-(3,5-dimethyl-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3,5-dimethyl-benzaldehyde with methyl dichloro-acetate. 3-(3-Bromo-4-fluoro-phenyl)-3-chloro-2-oxo-propionic acid methyl ester prepared by reaction of 3-bromo-4-fluoro-benzaldehyde with methyl dichloro-acetate. 3-Chloro-3-(3,4-dichloro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3,4-dichloro-benzaldehyde with methyl dichloro-acetate. 3-Chloro-3-(3,4-difluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3,4-difluoro-benzaldehyde with methyl dichloro-acetate. 3-Chloro-3-(3-fluoro-4-methyl-phenyl)-2-oxo-propionic acid methyl ester Received at IPONZ on 20-Mar-2012 43 prepared by reaction of 3-fluoro-4-methyl-benzaldehyde with methyl dichloro-acetate. 3-Chloro-3-(3-fluoro-2-methyl-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3-fluoro-2-methyl-benzaldehyde with methyl dichloro-acetate. 3-Chloro-2-oxo-3-phenyl-propionic acid methyl ester prepared by reaction of benzaldehyde with methyl dichloro-acetate. 3-Chloro-3-(2,3-dichloro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 2,3-dichloro-benzaldehyde with methyl dichloro-acetate.
A. 1.2 Synthesis of thiazole-4-carboxylic acid methyl ester derivatives (general procedure) S o A solution of thioacetamide (132 mmol, 1.0 eq) in MeCN (250 mL) is added to a mixture of the respective 3-chloro-2-oxo-propionic ester derivative (132 mmol, 1.0 eq) and molecular sieves (4A, 12 g) in MeCN (60 mL). After stirring for 5 h the mixture is cooled in an ice-bath and the obtained precipitate is filtered off. The residue is washed with cold 15 MeCN, dried, dissolved in MeOH (280 mL) and stirred at 50°C for 6 h. The solvents are removed in vacuo to give the desired thiazole derivatives as a white solid. 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-2-oxo-3-m-tolyl-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.94 min; [M+H]+ = 248.0. 2-methyl-5-p-tolyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-2-oxo-3-p-tolyl-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.92 min; [M+H]+ = 248.2. -(3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-fluoro-phenyl)-2-oxo-propionic acid methyl ester 25 with thioacetamide. LC-MS: tR = 0.91 min; [M+H]+ = 252.1. -(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester Received at IPONZ on 20-Mar-2012 44 prepared by reaction of 3-chloro-3-(4-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. *H-NMR (CDC13): 5 = 2.75 (s, 3H); 3.84 (s, 3H); 7.10 (m, 2H); 7.47 (m, 2H). -(3-chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-chloro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.95 min; [M+H]+ = 268.0. -(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3,4-dimethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.96 min; [M+H]+ = 262.3. 2-Methyl-5-phenyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-2-oxo-3-phenyl-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.87 min; [M+H]+ = 234.3. -(2,3-Dichloro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(2,3-dichloro-phenyl)-2-oxo-propionic acid methyl 15 ester with thioacetamide. LC-MS: tR = 0.97 min; [M+H]+ = 302.2. -(3-Fluoro-2-methyl-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-fluoro-2-methyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.93 min; [M+H]+ = 266.3. -(3-Bromo-4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-(3-bromo-4-fluoro-phenyl)-3-chloro-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.95 min; [M+H]+ = 330.2. -(3,4-Dichloro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3,4-dichloro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.99 min; [M+H]+ = 302.2. 5-(3,4-Difluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3,4-difluoro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.92 min; [M+H]+ = 270.3. -(3-Fluoro-4-methyl-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-fluoro-4-methyl-phenyl)-2-oxo-propionic acid 30 methyl ester with thioacetamide. LC-MS: tR = 1.00 min; [M+H]+ = 266.0.
Received at IPONZ on 20-Mar-2012 45 -(3,5-Dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3,5-dimethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.97 min; [M+H]+ = 262.3.
A. 1.3 Synthesis of 2-cyclopropyl-thiazole-4-carboxylic acid methyl ester derivatives 5 Synthesis of cyclopropanecarbothioic acid amide 2,4-Bis-(4-methoxyphenyl)-l,3-dithia-2,4-diphosphetane 2,4-disulfide (Lawesson reagent, 173 mmol) is added to a mixture of cyclopropanecarboxamide (173 mmol) and Na2CC>3 (173 mmol) in THF (750 mL). The reaction mixture is stirred at reflux for 3h, concentrated in vacuo and diluted with ether (500 mL) and water (500 mL). The layers are separated and 10 the aq. layer is extracted with ether (250 mL). The combined organic layers are washed with brine (100 mL), dried over MgS04 and concentrated in vacuo to give a crude product which is used without further purification. ^-NMR (DMSO-de): 5 = 0.81-0.88 (m, 2H); 0.96-1.00 (m, 2H); 2.00 (tt, J = 8.0 Hz, J = 4.3 Hz, 1H); 9.23 (bs, 1H); 9.33 (bs, 1H).
Synthesis of 2-cyclopropyl-thiazole-4-carboxylic acid methyl ester derivatives 15 (general procedure) S O A solution of cyclopropanecarbothioic acid amide (33.9 mmol, 1.0 eq) in MeCN (45 mL) is added to a mixture of the respective 3-chloro-2-oxo-propionic ester derivative (33.9 mmol, 1.0 eq) and NaHCC>3 (102 mmol, 3.0eq) in MeCN (45 mL). After stirring for 2d at 20 rt the mixture is concentrated in vacuo and the residue is diluted with EtOAc (150 mL) and water (150 mL). The layers are separated and the aq. layer is extracted with EtOAc (100 mL). The combined organic layers are washed with brine (100 mL), dried over MgS04 and concentrated in vacuo. The residue is dissolved in MeOH (70 mL) and treated with concentrated H2S04 (0.18 mL). The mixture is stirred at 60°C for 16 h and concentrated in 25 vacuo to give the respective crude product which is used without further purification. 2-Cyclopropyl-5-phenyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-2-oxo-3-phenyl-propionic acid methyl ester with cyclopropanecarbothioic acid amide. LC-MS: tR = 0.99 min; [M+H]+ = 260.5.
Received at IPONZ on 20-Mar-2012 46 2-Cyclopropyl-5-(4-methyl-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-2-oxo-3-(4-methyl-phenyl)-propionic acid methyl ester with cyclopropanecarbothioic acid amide. LC-MS: tR = 0.99 min; [M+H]+ = 260.5.
A. 1.4 Synthesis of 2-amino-thiazole-4-carboxylic acid methyl ester derivatives 5 (general procedure) S O A solution of the respective 3-chloro-2-oxo-propionic ester derivative (22.1 mmol, 1.0 eq) in acetone (25 mL) is added to a suspension of thiourea (22.1 mmol, 1.0 eq) in acetone (45 mL). The mixture is heated to 57°C (bath temperature), stirred for 24h and concentrated to 10 half of the volume. The obtained suspension is filtered and the residue is washed with acetone. After drying the desired amino-thiazole derivative is obtained as a solid. 2-Amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tR = 0.78 min; [M+H]+ = 252.9. 2-Amino-5-(2-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(2-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tR = 0.76 min; [M+H]+ = 253.2. 2-Amino-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(4-fluoro-phenyl)-2-oxo-propionic acid methyl ester 20 with thiourea. LC-MS: tR = 0.75 min; [M+H]+ = 253.2. 2-Amino-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-methoxy-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tR = 0.75 min; [M+H]+ = 265.3. 2-Amino-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-chloro-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tR = 0.82 min; [M+H]+ = 269.2.
Received at IPONZ on 20-Mar-2012 47 2-Amino-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-trifluoromethyl-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tR = 0.86 min; [M+H]+ = 303.3. 2-Amino-5-phenyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-2-oxo-3-phenyl-propionic acid methyl ester with thiourea. LC-MS: tR = 0.77 min; [M+H]+ = 235.1.
A.1.5 Synthesis of 2-bromo-thiazole-4-carboxylic acid methyl ester derivatives (general procedure) At 15°C under an atmosphere of nitrogen the respective 2-amino-thiazole-4-carboxylic acid methyl ester (7.10 mmol) is added portionwise to a mixture of CuBr2 (7.10 mmol) and isoamyl nitrite (10.6 mmol) in MeCN (30 mL). The mixture is stirred for 20 min at 15°C, for 30 min at 40°C and for 90 min at 65°C. The solvents are removed in vacuo and the crude product is either purified by flash chromatography (DCM/MeOH or EtOAc/heptane) 15 or used without further purification. 2-Bromo-5-(2-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 2-amino-5-(2-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester with CuBr2 and isoamyl nitrite. LC-MS: tR = 0.96 min; [M+H]+ = 316.1. 2-Bromo-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 2-amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester with CuBr2 and isoamyl nitrite. LC-MS: tR = 1.08 min; [M+H]+ = 316.0. 2-Bromo-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 2-amino-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester with CuBr2 and isoamyl nitrite. LC-MS: tR = 0.97 min; [M+H]+ = 316.1. 2-Bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 2-amino-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester with CuBr2 and isoamyl nitrite. LC-MS: tR = 0.97 min; [M+H]+ = 328.2.
Received at IPONZ on 20-Mar-2012 48 2-Bromo-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 2-amino-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl ester with CuBr2 and isoamyl nitrite. LC-MS: tR = 1.00 min; [M+H]+ = 332.2. 2-Bromo-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 2-amino-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester with CuBr2 and isoamyl nitrite. LC-MS: tR = 1.03 min; [M+H]+ = 366.2. 2-Bromo-5-phenyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 2-amino-5-phenyl-thiazole-4-carboxylic acid methyl ester with CuBr2 and isoamyl nitrite. LC-MS: tR = 1.07 min; [M+H]+ = 297.9.
A.1.6 Synthesis of thiazole-4-carboxylic acid methyl ester derivatives lacking a substituent in 2-position (general procedure) A solution/suspension of the respective 2-bromo-thiazole-4-carboxylic acid methyl ester (3.17 mmol) in EtOH (20 mL) is added to a suspension of Pd/C (600 mg, 10%) in EtOH 15 (20 mL) and stirred under a hydrogen atmosphere (1 bar) for 18 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. -(2-Fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by hydrogenation of 2-bromo-5-(2-fluoro-phenyl)-thiazole-4-carboxylic acid 20 methyl ester. LC-MS: tR = 0.91 min; [M+H]+ = 238.0. -(4-Fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by hydrogenation of 2-bromo-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.92 min; [M+H]+ = 238.1. -(3-Methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by hydrogenation of 2-bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.92 min; [M+H]+ = 250.1. -(3-Chloro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by hydrogenation of 2-bromo-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.91 min; [M+H]+ = 253.9.
H2, Pd/C Received at IPONZ on 20-Mar-2012 49 -(3-Trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by hydrogenation of 2-bromo-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.99 min; [M+H]+ = 288.0.
A.1.7 Synthesis of thiazole-4-carboxylic acid derivatives 5 (general procedure) A solution of the respective thiazole-4-carboxylic acid ester (96.2 mmol) in a mixture of THF (150 mL) and either MeOH or isopropanol (50 mL) is treated with an aq. NaOH solution (1.0 M, 192 mL). After stirring for 3 h a white suspension is formed and the 10 organic volatiles are removed in vacuo. The remaining mixture is diluted with water (100 mL), cooled in an ice-bath and made acidic (pH = 3-4) by addition of aq. HCI solution (1.0 M). The suspension is filtered and the residue is washed with cold water. After drying the desired acid is obtained as a white solid. 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.83 min; [M+H]+ = 234.0. 2-methyl-5-p-tolyl-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-p-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.83 min; [M+H]+ = 234.0. 5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.82 min; [M+H]+ = 238.1. -(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid 25 methyl ester. !H-NMR (DMSO-d6): 5 = 2.67 (s, 3H); 7.27 (m, 2H); 7.53 (m, 2H); 12.89 (bs, 1H). -(3-chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3-chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.84 min; [M+H]+ = 254.0.
NaOH Received at IPONZ on 20-Mar-2012 50 -(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.86 min; [M+H]+ = 248.3. 2-amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.62 min; [M+H]+ = 239.1. 2-Methyl-5-phenyl-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-phenyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.77 min; [M+H]+ = 220.3. 5-(2,3-Dichloro-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(2,3-dichloro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.86 min; [M+H]+ = 288.2. -(3-Fluoro-2-methyl-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3-fluoro-2-methyl-phenyl)-2-methyl-thiazole-4-carboxylic 15 acid methyl ester. LC-MS: tR = 0.83 min; [M+H]+ = 252.2. -(3-Bromo-4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3-bromo-4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.86 min; [M+H]+ = 316.2. -(3,4-Dichloro-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3,4-dichloro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.88 min; [M+H]+ = 288.2. -(3,4-Difluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3,4-difluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.82 min; [M+H]+ = 256.3. 5-(3-Fluoro-4-methyl-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3-fluoro-4-methyl-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.89 min; [M+H]+ = 252.0. -(3,5-Dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3,5-dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid 30 methyl ester. LC-MS: tR = 0.86 min; [M+H]+ = 248.3.
Received at IPONZ on 20-Mar-2012 51 -(3-Trifluoromethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3-trifluoromethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.91 min; [M+H]+ = 288.03. -(2-Fluoro-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 5-(2-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.80 min; [M+H]+ = 224.1. -(3-Methoxy-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.81 min; [M+H]+ = 236.1. 5-(3-Chloro-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.85 min; [M+H]+ = 240.0. -( 3-1 rifluoromethyl-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid 15 methyl ester. LC-MS: tR = 0.89 min; [M+H]+ = 274.0. -(4-Fluoro-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.80 min; [M+H]+ = 224.1. 2-Cyclopropyl-5-phenyl-thiazole-4-carboxylic acid prepared by saponification of 2-cyclopropyl-5-phenyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.91 min; [M+H]+ = 246.4. 2-Cyclopropyl-5-p-tolyl-thiazole-4-carboxylic acid prepared by saponification of 2-cyclopropyl-5-p-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.91 min; [M+H]+ = 260.03. 2-Cyclopropyl-5-(2-fluoro-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-cyclopropyl-5-(2-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.91 min; [M+H]+ = 264.27. 2-Cyclopropyl-5-m-tolyl-thiazole-4-carboxylic acid prepared by saponification of 2-cyclopropyl-5-m-tolyl-thiazole-4-carboxylic acid methyl 30 ester. LC-MS: tR = 0.90 min; [M+H]+ = 260.23.
Received at IPONZ on 20-Mar-2012 52 2-Cyclopropyl-5-(3-fluoro-4-methyl-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-cyclopropyl-5-(3-fluoro-4-methyl-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.97 min; [M+H]+ = 278.06. 2-Cyclopropyl-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-cyclopropyl-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.92 min; [M+H]+ = 264.01.
A.l.8.1 Synthesis of 2-dimethylamino-thiazole-4-carboxylic acid derivatives (general procedure) An aq. solution of dimethylamine (40%, 13 mL) is added to a solution of the respective 2-bromo-thiazole-4-carboxylic acid methyl ester derivative (6.71 mmol) in MeCN (38 mL). After 2h an additional portion of an aq. dimethylamine solution (40%, 13 mL) is added. After stirring at rt for 2d THF (13.6 mL), MeOH (6.8 mL) and aq. NaOH solution (1.0 M, 13.4 mL) are added successively and the mixture is stirred for 16h. The solvents are 15 removed in vacuo and the residue is diluted with water (30 mL). The suspension is made acidic (pH 3) by addition of aq. citric acid (10%) and extracted three times with EtOAc. The combined organic layers are washed twice with brine, dried over MgS04 and concentrated in vacuo to give the desired acid which is used without further purification. 2-Dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid 20 prepared by reaction of 2-bromo-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester with dimethylamine. LC-MS: tR = 0.87 min; [M+H]+ = 267.0. 2-Dimethylamino-5-phenyl-thiazole-4-carboxylic acid prepared by reaction of 2-bromo-5-phenyl-thiazole-4-carboxylic acid methyl ester with dimethylamine. LC-MS: tR = 0.81 min; [M+H]+ = 249.1. 2-Dimethylamino-5-(3,4-dimethyl-phenyl)-thiazole-4-carboxylic acid prepared by reaction of 2-bromo-5-(3,4-dimethyl-phenyl)-thiazole-4-carboxylic acid methyl ester with dimethylamine. LC-MS: tR = 0.89 min; [M+H]+ = 277.3. -(3-Chloro-phenyl)-2-dimethylamino-thiazole-4-carboxylic acid prepared by reaction of 2-bromo-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl 30 ester with dimethylamine. LC-MS: tR = 0.90 min; [M+H]+ = 283.21.
Received at IPONZ on 20-Mar-2012 53 2-Dimethylamino-5-(2-fluoro-phenyl)-thiazole-4-carboxylic acid prepared by reaction of 2-bromo-5-(2-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester with dimethylamine. LC-MS: tR = 0.84 min; [M+H]+ = 267.42. 2-Dimethylamino-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid prepared by reaction of 2-bromo-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester with dimethylamine. LC-MS: tR = 0.83 min; [M+H]+ = 267.27. 2-Dimethylamino-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid prepared by reaction of 2-bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester with dimethylamine. LC-MS: tR = 0.83 min; [M+H]+ = 279.25.
According to the procedure described above, the following 2-amino-5-aryl-thiazole-4-carboxylic acid derivatives were prepared: -(3-Chloro-phenyl)-2-diethylamino-thiazole-4-carboxylic acid prepared by reaction of 2-bromo-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl ester with diethylamine. LC-MS: tR = 0.92 min; [M+H]+ = 311.21. 5-(3-Chloro-phenyl)-2-ethylmethylamino-thiazole-4-carboxylic acid prepared by reaction of 2-bromo-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl ester with ethylmethylamine. LC-MS: tR = 0.90 min; [M+H]+ = 297.22.
A.l.8.2. Synthesis of 2-alkoxy-thiazole-4-carboxylic acid derivatives (general procedure) The alcohol (3 mmol) is slowly added to a suspension of sodium hydride (3 mmol) in THF (4 ml) and stirring is continued for 15 min at rt followed by the addition of a solution of the respective 2-bromo-thiazole-4-carboxylic acid methyl ester derivative (1.5 mmol) in THF / DMF (6 ml / 0.7 ml). After stirring at rt for 2d THF (13.6 mL), MeOH (6.8 mL) and aq.
NaOH solution (1.0 M, 13.4 mL) are added successively and the mixture is stirred for 16h. The solvents are removed in vacuo and the residue is diluted with water (30 mL). The suspension is made acidic (pH 3) by addition of aq. citric acid (10%) and extracted three times with EtOAc. The combined organic layers are washed twice with brine, dried over MgS04 and concentrated in vacuo to give the desired acid which is used without further purification.
Received at IPONZ on 20-Mar-2012 54 -(3-Chloro-phenyl)-2-methoxy-thiazole-4-carboxylic acid LC-MS: tR = 0.93 min; [M+H]+ = 271.24. -(3-Chloro-phenyl)-2-(2-methoxy-ethoxy)-thiazole-4-carboxylic acid LC-MS: tR = 0.95 min; [M+H]+ = 314.00. 5-(3-Chloro-phenyl)-2-ethoxy-thiazole-4-carboxylic acid LC-MS: tR = 0.93 min; [M+H]+ = 284.01.
A.1.9 Synthesis of 2-methyl-oxazole-4-carboxylic acid derivatives A.l.9.1 Synthesis of 2-acetylamino-3-oxo-propionic acid methyl ester derivatives (general procedure) A solution of the respective 3-oxo-propionic acid methyl ester derivative (4.8 mmol, 1.0 eq.) in glacial acetic acid (1.9 mL) was cooled to 10°C and at this temperature was added a solution of NaN02 (5.6 mmol, 1.16 eq.) in water (0.68 mL). After the addition was complete (15 min), the solution was allowed to warm to rt and stirred for 2 h. Then the 15 solution was poured into water (10 mL) and after a few minutes crystals begun to appear. This suspension was cooled in an ice-bath and crystals were collected by filtration. The cake was washed several times with cold water and the water was removed by the azeotrope of toluene-water in vacuo to give 2-hydroxyimino-3-oxo-propionic acid methyl ester derivatives which were dissolved in a mixture of acetic anhydride (1.4 mL) and 20 glacial acetic acid (1.8 mL). To this solution was added sodium acetate (0.296 mmol, 0.06 eq.) and HgCl2 (0.01 mmol, 0.002 eq.). The mixture was refluxed for 1 h, then cooled to rt and filtered. The solid was rinsed with ether, the organic filtrate was recovered, washed 3 times with water and one time with 1M aq. K2CO3. The organic layer was dried over MgS04, filtered and concentrated. The crude products were purified by flash 25 chromatography to afford the corresponding 2-acetylamino-3-oxo-propionic acid methyl ester derivatives. 2-Acetylamino-3-oxo-3-(3-trifluoromethoxy-phenyl)-propionic acid methyl ester prepared according to general procedure A.l.9.1 from 3-oxo-3-(3-trifluoromethoxy-phenyl)-propionic acid methyl ester.
O O Received at IPONZ on 20-Mar-2012 55 A.l.9.2 Synthesis of 2-methyl-oxazole-4-carboxylic acid derivatives (general procedure) A solution of the respective 2-acetylamino-3-oxo-propionic acid methyl ester derivative (0.63 mmol, 1.0 eq.) in CHC13 (0.4 mL) was cooled to 0°C in an ice/NaCl bath. SOCl2 (0.88 mmol, 1.4 eq.) was added to the stirred solution and the temperature was maintained at 0°C for 30 minutes. Then the solution was stirred and refluxed for one hour. Another 0.25 eq. of SOCl2 was added and the reaction mixture was refluxed for another hour. The excess SOCl2 was quenched with 1M aq. K2C03. The aq. layer was extracted twice with ether. The combined organic phases were washed once with water and dried over MgS04, filtered and concentrated yielding the corresponding 2-methyl-oxazole-4-carboxylic acid methyl ester derivative. The respective 2-methyl-oxazole-4-carboxylic acid methyl ester derivative was dissolved in a mixture of EtOH (0.7 ml) and 2N aq. NaOH (0.7 mL, 2.5 eq.). The mixture was stirred at rt for 2 hours. The reaction mixture was washed once with ether and this organic layer was discarded. The aq. layer was then acidified with conc. HCI and extracted twice with ether. Both organic layers were combined, dried over MgS04 and concentrated in vacuo to afford the corresponding 2-methyl-oxazole-4-carboxylic acid derivatives. 2-Methyl-5-(3-trifluoromethoxy-phenyl)-oxazole-4-carboxylic acid prepared according to general procedure A.l.9.2 from 2-acetylamino-3-oxo-3-(3-trifluoromethoxy-phenyl)-propionic acid methyl ester acid methyl ester. LC-MS: tR = 0.95 min; [M-H]+ = 287.86.
A.1.10 Synthesis of 3-aryl-thiophene-2-carboxylic acid derivatives A.l.10.1 3-(3-Methoxy-phenyl)-thiophene-2-carboxylic acid O O B B NaOH O K2CO3 (2M) OMe i-PrOH / Toluene Pd(PPh3)4 OMe Received at IPONZ on 20-Mar-2012 56 3-Bromothiophene-2-carboxylic acid (600 mg; 2.9 mmol) was dissolved in isopropanol (7 ml) / toluene (7 ml), followed by the addition of K2CO3 solution (aq; 2M; 9 ml) and 3-methoxybenzeneboronic acid (440 mg; 2.9 mmol). The reaction mixture was deoxygenized with N2 (g) for 3 minutes followed by the addition of tetrakis-(triphenylphosine)-palladium 5 and subsequently heated to 80°C for 14 h. The mixture was cooled to rt, ether was added and the organic layer was extracted with 2M NaOH-solution. The aq. layer was acidified by the addition of 2M HCI. The product precipitated and was filtered off and dried at high vacuum to give 470 mg of 3-(3-methoxy-phenyl)-thiophene-2-carboxylic acid; LC-MS: tR = 0.94 min; [M-H]+ = 235.27.
A.l.10.2 3-(3,4-Dimethoxy-phenyl)-thiophene-2-carboxylic acid According to the procedure described above 400 mg of 3-(3,4-dimethoxy-phenyl)-thiophene-2-carboxylic acid {LC-MS: tR = 0.88 min; [M-H]+ = 265.24.} was obtained from 3-Bromothiophene-2-carboxylic acid (600 mg; 2.9 mmol) and 3,4-dimethoxyboronic acid (527 mg; 2.9 mmol).
A.l.10.3 3-Benzo[l,3]dioxol-5-yl-thiophene-2-carboxylic acid According to the procedure described above 430 mg of 3-Benzo[l,3]dioxol-5-yl-thiophene-2-carboxylic acid {LC-MS: tR = 0.93 min; [M-H]+ = 290.22.} was obtained from 3-Bromothiophene-2-carboxylic acid (600 mg; 2.9 mmol) and 3,4-(methylenedioxy)phenylboronic acid (480 mg; 2.9 mmol).
A.l.10.4 3-(4-Methoxy-phenyl)-thiophene-2-carboxylic acid According to the procedure described above 424 mg of 3-(4-Methoxy-phenyl)-thiophene-2-carboxylic acid {LC-MS: tR = 0.94 min; [M-H]+ = 276.22.} was obtained from 3-Bromothiophene-2-carboxylic acid (600 mg; 2.9 mmol) and 4-methoxyphenylboronic acid (440 mg; 2.9 mmol).
A.1.11. Synthesis of 3-aryl-pyrazine-2-carboxylic acids: A. 1.11.1 3-p-Tolyl-pyrazine-2-carboxylic acid 3-Chloropyrazine-2-carbonitrile (3.0 g; 21.5 mmol) was dissolved in dimethoxyethane (65 ml) and 4-tolylboronic acid (3.2 g; 23.65 mmol) was added, followed by the addition of B(OH)2 DME; K2C03 2M ^ Pd(OAc)2 f PPh3 Received at IPONZ on 20-Mar-2012 57 K2C03 (8.2 g; 59 mmol) and water (30 ml). The reaction mixture was deoxygenized with N2 (g) for 3 minutes followed by the addition of triphenylphosphine (842 mg; 3.2 mmol) and palladium(II)acetate (237 mg; 1.06 mmol). The reaction mixture was heated to 90°C for 14 h, cooled to rt, diluted with EtOAc, filtered over a plug of celite and dried with 5 magnesiumsulfate. The organic solvent was evaporated under reduced pressure to give 5.3 g of 3-p-tolyl-pyrazine-2-carbonitrile. The intermediate nitrile was dissolved in MeOH (110 ml) followed by the addition of 4M aq NaOH (180 ml). The resulting mixture was heated to 85°C for 14 h, cooled to rt and the MeOH was evaporated under reduced pressure. The residual aq. phase was acidified to pH=2 by the addition of conc. HCI and 10 the precipitated product was filtered off, dissolved in DCM / EtOAc and dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 2.30 g of 3-p-tolyl-pyrazine-2-carboxylic acid. LC-MS: tR = 0.40 min; [M-H]+ = 213.14.
A.l.11.2 3-(3,4-Dimethyl-phenyl)-pyrazine-2-carboxylic acid According to the procedure described above 3.8 g of 3-(3,4-Dimethyl-phenyl)-pyrazine-2-15 carboxylic acid was prepared. LC-MS: tR = 0.50 min; [M-H]+ = 227.07.
A.l.11.3 3-(lH-Indol-6-yl)-pyrazine-2-carboxylic acid According to the procedure described above 540 mg of 3-(lH-Indol-6-yl)-pyrazine-2-carboxylic acid was prepared. LC-MS: tR = 0.72 min; [M-H]+ = 240.25.
A.2 Synthesis of benzo[l,4]oxazine-carboxylic acid derivatives 20 A.2.1 Synthesis of 2-amino-3-hydroxy-benzoic acid methyl ester A solution of (trimethylsilyl)diazomethane in hexane (2.0 M, 10.9 mmol) is added dropwise (10 min) to a mixture of 3-hydroxyanthranilic acid (9.93 mmol) in MeOH (10.5 mL) and toluene (42 mL). The mixture is stirred for 16h, concentrated in vacuo, diluted with ether and EtOAc and washed several times with water. The organic layer is dried over 25 MgS04 and concentrated under reduced pressure. The residue is purified by flash chromatography (gradient: heptane to heptane/EtOAc 7/3) to give the desired ester as a brown solid. LC-MS: tR = 0.70 min; [M+H]+ = 168.0.
A.2.2 Synthesis of 3-oxo-3,4-dihydro-2H-benzo[l,4]oxazine-5-carboxylic acid methyl ester At rt chloro-acetyl chloride (8.06 mmol) is added dropwise to a solution of 2-amino-3-hydroxy-benzoic acid methyl ester (7.33 mmol) in DMF (50 mL). After 20 min K2CO3 (34.9 mmol) is added portionwise, the mixture is stirred for 16h at rt and the solvents are Received at IPONZ on 20-Mar-2012 58 removed in vacuo. Water and DCM are added, the layers are separated and the organic layer is washed with brine and dried over Na2S04. The solvents are removed in vacuo to give a crude product which is purified by flash chromatography (gradient: heptane to heptane/EtOAc 6/4). LC-MS: tR = 0.82 min; [M+CH3CN+H]+ = 249.0.
A.2.3 Synthesis of 3,4-dihydro-2H-benzo[l,4]oxazine-5-carboxylic acid methyl ester Boron trifluoride diethyl etherate (7.10 mmol) is added dropwise to a mixture of 3-oxo-3,4-dihydro-2H-benzo[l,4]oxazine-5-carboxylic acid methyl ester (3.38 mmol) in THF (10 mL) to keep the temperature below 5°C. After 20 min NaBH4 (7.10 mmol) is added and the mixture is stirred at 5°C for 90 min. EtOAc (6.0 mL) and hydrochloric acid (1.0 M, 6.0 10 mL) are added dropwise. The mixture is made basic by addition of aq. Na2C03 solution, the layers are separated and the aq. layer is extracted with EtOAc. The combined organic layers are dried over MgS04 and concentrated in vacuo to give a crude product which is purified by flash chromatography (gradient: heptane to heptane/EtOAc 3/7). LC-MS: tR = 0.90 min; [M+CH3CN+H]+ = 235.3.
A.2.4 Synthesis of benzo[l,4]oxazine-carboxylic acid derivatives by ester hydrolysis (general procedure) A solution of NaOH (4.00 mmol) in a mixture of MeOH (3.0 mL) and water (6.8 mL) is added to the respective ester derivative (2.00 mmol). The mixture is stirred at 55°C for 16h, partially concentrated in vacuo to remove MeOH and made acidic by addition of 20 hydrochloric acid (1.0M). The respective carboxylic acid precipitates and is collected by filtration. 3,4-dihydro-2H-benzo [ 1,4] oxazine-5-carboxylic acid prepared by saponification of 3,4-dihydro-2H-benzo[l,4]oxazine-5-carboxylic acid methyl ester. LC-MS: tR = 0.76 min; [M+H]+ = 180.2.
A.3 Synthesis of 2,3,6,7-Tetrahydro-benzo[l,2-b;4,5-b']difuran-4-carboxylic acid 4-Formyl-2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuran (0.25 mmol; Lit.: A. P. Monte, D. Marona-Lewicka, M. A. Parker, D. B. Wainscott, D. L. Nelson, D. E. Nichols J. Med. Chem., 1996, 39, 2953-2961) is added to a stirred suspension of silver(I) oxide (0.375 mmol) in an aq. NaOH solution (5%, 0.20 mL). The mixture is stirred for 5 h, filtered and 30 washed with water (2.0 mL). The filtate is cooled to 0°C and made acidic by dropwise addition of hydrochloric acid (25%). The obtained suspension is filtered off and washed with ice-cold water and heptane. The residue is dried in vacuo to give the desired acid as a Received at IPONZ on 20-Mar-2012 59 grey powder which is used without further purification. LC-MS (basic): tR = 0.20 min; [M-H]" = 205.2.
A.4 Synthesis of benzothiazole-7-carboxylic acid A.4.1 Synthesis of 3-thioureido-benzoic acid methyl ester At -10°C sulfuric acid (0.46 mL) is added dropwise to a solution of methyl 3-aminobenzoate (17.2 mmol) in chlorobenzene (19 mL). After 15 min potassium thiocyanate (18.2 mmol) is added portionwise over 30 min. The mixture is treated with 18-crown-6 (0.18 mmol), heated to 100°C for 16h and allowed to cool to rt. After 4h the obtained precipitate is filtered off and washed successively with chlorobenzene (33 mL) 10 and hexane (three times 130 mL). The residue is diluted with water (390 mL) and the suspension is stirred for 30 min. After filtration the residue is washed twice with water (130 mL each), concentrated in vacuo and dried additionally by azeotropic removal of water with toluene. The obtained product is used without further purification. LC-MS: tR = 0.66 min; [M+H]+= 211.0.
A.4.2 Synthesis of 2-amino-benzothiazole-7-carboxylic acid methyl ester At 0°C a solution of bromine (13.4 mmol) in acetic acid (9.4 mL) is added dropwise to a vigorously stirred solution of 3-thioureido-benzoic acid methyl ester (12.5 ml) in acetic acid (37 mL). The mixture is allowed to reach rt, stirred at 70°C for 4h and cooled to rt. Ether is added and the precipitate is filtered off. The residue is stirred vigorously in a sat 20 aq. NaHCC>3 solution, filtered off and washed with water. The obtained solid is dried in vacuo to give the desired product which is used without further purification. LC-MS: tR = 0.62 min; [M+H]+ = 209.0.
A.4.3 Synthesis of benzothiazole-7-carboxylic acid methyl ester Isoamyl nitrite (22.0 mmol) is added to a solution of 2-amino-benzothiazole-7-carboxylic 25 acid methyl ester (10.1 mmol) in THF (29 mL). The mixture is heated to reflux for 4h, the solvents are removed in vacuo and the residue is purified by flash chromatography (gradient: heptane to EtOAc/heptane 4/6) to give the desired product. LC-MS: tR = 0.85 min; [M+H]+= 194.0.
A.4.4 Synthesis of benzothiazole-7-carboxylic acid At 0°C an aq. NaOH solution (50%, 6.0 mL) is added to a solution of benzothiazole-7-carboxylic acid methyl ester in a mixture of MeOH (39 mL), THF (11.7 mL) and water (3.0 mL). The mixture is stirred for 4h and concentrated in vacuo. At 0°C water (60 mL) is Received at IPONZ on 20-Mar-2012 60 added and the mixture is made acidic (pH 5) by addition of conc. hydrochloric acid. After 30 min the precipitate is filtered off, washed with water and dried in vacuo to give the desired product. LC-MS: tR = 0.77 min; [M+CH3CN+H]+ = 221.1.
A.5 Synthesis of 6-methyl-pyrrolo[2,l-b]thiazole-7-carboxylic acid 5 A.5.1 Synthesis of 6-bromo-pyrrolo[2,l-b]thiazole-7-carboxylic acid ethyl ester N-Bromosuccinimide (0.56 mmol) is added to a solution of pyrrolo[2,l-b]thiazole-7-carboxylic acid ethyl ester (0.56 mmol) in DCM (6.0 mL). After 30 min water (5.0 mL) is added, the layers are separated and the aq. layer is extracted with DCM (5.0 mL). The combined organic layers are dried over Na2S04 and the solvents are removed in vacuo to 10 give the desired product which is used without further purification. LC-MS: tR = 1.02 min; [M+H]+ = 273.9.
A.5.2 Synthesis of 6-methyl-pyrrolo[2,l-b]thiazole-7-carboxylic acid ethyl ester Under nitrogen atmosphere a solution of dimethylzinc in toluene (1.2 M, 19.1 mL) is added to a mixture of 6-bromo-pyrrolo[2,l-b]thiazole-7-carboxylic acid ethyl ester (11.4 15 mmol) and [l,r-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.23 mmol, complex with CH2CI2) in dioxane (35 mL). The mixture is heated to reflux for 2h, stirred at rt for 12h and diluted by addition of MeOH (2.3 mL) and TBME. The mixture is washed with hydrochloric acid (1.0 M) and water, dried over MgS04, concentrated in vacuo and purified by flash chromatography (gradient: heptane to heptane/EtOAc 8/2) to give the 20 desired product. LC-MS: tR = 0.91 min; [M+H]+ = 210.0.
A.5.3 Synthesis of 6-methyl-pyrrolo[2,l-b]thiazole-7-carboxylic acid A mixture of 6-methyl-pyrrolo[2,l-b]thiazole-7-carboxylic acid ethyl ester (7.29 mmol) and NaOH (10.9 mmol) in EtOH (11.8 mL) and water (11.8 mL) is heated to 75°C for 3d. The mixture is concentrated in vacuo and made acidic by addition of hydrochloric acid (1.0 25 M). The obtained precipitate is filtered off and dried in vacuo to give the desired product. LC-MS: tR = 0.73 min; [M+H]+ = 182.0.
A.6 Synthesis of 2-Methyl-benzooxazole-4-carboxylic acid A.6.1 Synthesis of 2-Methyl-benzooxazole-4-carboxylic acid ethyl ester A mixture of 2-amino-3-hydroxy-benzoic acid ethyl ester (5.52 mmol; J. Reisch, G. M. K. 30 B. Gunaherath Monatshefte fur Chemie, 1988, 119, 1169-1178), acetyl chloride (6.07 mmol), NEt3 (6.07 mmo) and pyridinium p-toluenesulfonate (1.47 mmol) in xylene (60 mL) is heated at reflux for 16h, cooled to rt, diluted with EtOAc and washed with water.
Received at IPONZ on 20-Mar-2012 61 The organic layer is dried over MgS04 and concentrated in vacuo to give a crude product which is purified by flash chromatography (gradient: heptane to heptane/EtOAc 6/4). LC-MS: tR = 0.81 min; [M+H]+ = 206.0.
A.6.2 Synthesis of 2-Methyl-benzooxazole-4-carboxylic acid At 0°C an aq. KOH solution (1.0M, 2.40 mL) is added to a solution of 2-methyl-benzooxazole-4-carboxylic acid ethyl ester (0.98 mmol) in MeOH (5.0 mL) and stirred for 30 min. The mixture is allowed to reach rt, stirred for additional 60 min and made acidic by addition of aq. hydrochloric acid (2.0 M). After removal of MeOH under reduced pressure the obtained precipitate is filtered off to give the desired product which is dried in 10 vacuo. *H-NMR (DMSO-d6): 5 = 2.64 (s, 3H); 7.41 (t, J = 8.0 Hz, 1H); 7.83 (d, J = 7.8 Hz, 1H); 7.88 (d, J = 8.0 Hz, 1H); 12.8 (bs, 1H).
B Preparation of scaffolds B.l Synthesis of (lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester B.l.l Synthesis of (lR,3S,4S)-2-Aza-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 3-methyl ester A solution of (lS,3S,4R)-2-((R)-l-Phenyl-ethyl)-2-aza-bicyclo[2.2.1]hept-5-ene-3-carboxylic acid methyl ester (61.0 mmol; N. Hashimoto, H. Yasuda, M. Hayashi, Y. Tanabe Org. Proc. Res. Dev. 2005, 9, 105-109) in EtOH (100 mL) is treated with di-ieri-20 butyl dicarbonate (62.2 mmol, 1.02eq) and Pd/C (10%, 2.0 g). The mixture is stirred under a hydrogen atmosphere (7 bar) for 3d. After filtration through celite and removal of the solvents in vacuo the desired product is obtained which is used without further purification. *H-NMR (CDC13, 2 rotamers): 5 = 1.25-1.31 (m, 1H); 1.41 & 1.48 (2 s, 9H); 1.48-1.81 (m, 4H); 1.92-1.97 (m, 1H); 2.68 (bs, 1H); 3.74 (s, 3H); 3.75 & 3.86 (2 bs, 1H); 4.24 & 4.38 (2 25 bs, 1H).
B.1.2 Synthesis of (lR,3S,4S)-3-Hydroxymethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester At -78°C a solution of DIBAL in toluene (1.7M, 137 mmol) is added dropwise to a solution of (lR,3S,4S)-2-aza-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 30 3-methyl ester (61.0 mmol) in THF (180 mL). After 80 min the solution is allowed to reach rt, stirred for additional 2 h and poured into a mixture of aq. NaOH solution (1.0M, 200 mL) and ice. EtOAc (150 mL) is added, the layers are separated and the aq. layer is Received at IPONZ on 20-Mar-2012 62 extracted three times with EtOAc (150 mL each). The combined organic layers are washed with aq. NaOH solution (l.OM) and brine, dried over Na2S04 and concentrated in vacuo to give a crude product which is used without further purification. LC-MS (basic): tR = 0.78 min; [M+H]+= 228.3.
B.1.3 Synthesis of (lR,3S,4S)-3-Formyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester To a cold (-60°C) solution of oxalyl chloride (60.8 mmol) in dry DCM (130 mL) is added dropwise DMSO (111 mmol) within 5 min. After 15 min a solution of (lR,3S,4S)-3-hydroxymethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (50.7 mmol) 10 in dry DCM (40 mL) is added dropwise within 15 min. Stirring is continued for 45 min at -55°C, then DIPEA (253 mmol; dried over 3A molecular sieve) is added during 5 min. The reaction mixture is allowed to reach rt and diluted with water (250 mL). The layers are separated and the organic layer is washed twice with aq. citric acid (5%, 200 mL each) and twice with brine. The combined organic layers are dried over MgS04 and concentrated in 15 vacuo to give the desired product which is used without further purification. 1H-NMR (CDC13, 2 rotamers): 5= 1.31-1.37 (m, 1H); 1.44 & 1.50 (2 s, 9H); 1.58-1.84 (m, 5H); 2.78 & 2.81 (2 bs, 1H); 3.60 & 3.74 (2 bs, 1H); 4.26 & 4.41 (2 bs, 1H); 9.55 & 9.60 (2 bs, 1H).
B.1.4 Synthesis of (lR,3S,4S)-3-(Benzylamino-methyl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester Benzylamine (49.7 mmol) is added to a solution of (lR,3S,4S)-3-formyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (49.7 mmol) in DCM (200 mL). The mixture is treated with sodium triacetoxyborohydride (69.6 mmol), stirred for additional 20 min, poured into water (200 mL) and stirred vigorously for 10 min. The layers are separated and the aq. layer is extracted twice with DCM (2x100 mL). The 25 combined organic layers are washed with sat. NaHC03 solution (100 mL), water (100 mL) and brine (150 mL), dried over MgS04 and treated with activated charcoal (5 g). The mixture is filtered through celite and the filtrate is concentrated in vacuo to give the desired benzylamine which is used without further purification. LC-MS (basic): tR = 1.00 min; [M+H]+ = 317.3.
Received at IPONZ on 20-Mar-2012 63 B.1.5 Synthesis of (lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester A solution of (lR,3S,4S)-3-(benzylamino-methyl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (39.8 mmol) in EtOH (120 mL) is treated with Pd/C (10%, 5 4.0 g) and stirred under a hydrogen atmosphere (7 bar) for 1 d. An additional amount of Pd/C (1.0 g) is added and the mixture is stirred for further 6 h under a hydrogen atmosphere (7 bar). After filtration through celite and removal of the solvents in vacuo the desired amine is obtained which is used without further purification. LC-MS (basic): tR = 0.85 min; [M+H]+= 227.3.
B.2 Synthesis of (lR,3S,4S)-3-Acylaminomethyl-2-aza-bicyclo[2.2.1]heptane derivatives B.2.1 Synthesis of (lR,3S,4S)-3-Acylaminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester derivatives (general procedure) TBTU (0.73 mmol, 1.1 Oeq) is added to a solution of the respective carboxylic acid (0.70 mmol, 1.05eq) and DIPEA (1.66 mmol, 2.5eq) in DCM (1.0 mL) and DMF (0.25 mL). After 10 min a solution of (lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (0.66 mmol, l.Oeq) in DCM (1.0 mL) is added and the mixture is stirred for 2h and washed twice with water (1.0 mL). The organic layer is dried 20 over MgS04, the solvents are removed in vacuo and the residue is purified by prep. HPLC to give the respective amide. (lR,3S,4S)-3-{[(Benzofuran-4-carbonyl)-amino]-methyl}-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester prepared by reaction of (lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-25 carboxylic acid tert-butyl ester with benzofuran-4-carboxylic acid (M.A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105). LC-MS (basic): tR = 0.97 min; [M+H]+ = 371.1. (lR,3S,4S)-3-{[(Quinoline-8-carbonyl)-amino]-methyl}-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester t-BuO t-BuO Received at IPONZ on 20-Mar-2012 64 prepared by reaction of (lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester with quinoline-8-carboxylic acid. LC-MS (basic): tR = 0.95 min; [M+H]+ = 382.2. (lR,3S,4S)-3-{[(2,3-Dihydro-benzo[l,4]dioxine-5-carbonyl)-amino]-methyl}-2-aza-5 bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester prepared by reaction of (lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester with 2,3-dihydro-benzo[l,4]dioxine-5-carboxylic acid. LC-MS (basic): tR = 0.91 min; [M+H]+ = 389.1. (lR,3S,4S)-3-{[(6-Methyl-imidazo[2,l-b]thiazole-5-carbonyl)-amino]-methyl}-2-aza- bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester prepared by reaction of (lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester with 6-methyl-imidazo[2,l-b]thiazole-5-carboxylic acid. LC-MS (basic): tR = 0.88 min; [M+H]+ = 391.1. (lR,3S,4S)-3-{[(2-Ethyl-5-methyl-2H-pyrazole-3-carbonyl)-amino]-methyl}-2-aza-15 bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester prepared by reaction of (lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester with 2-ethyl-5-methyl-2H-pyrazole-3-carboxylic acid. LC-MS (basic): tR = 0.92 min; [M+H]+ = 363.0.
B.2.2 Synthesis of (lR,3S,4S)-3-Acylaminomethyl-2-aza-bicyclo[2.2.1]heptane 20 derivatives (general procedure) A solution of HCI in dioxane (4.0 M, 2.0 mL) is added to a solution of the respective Boc-protected 2-aza-bicyclo[2.2.1]heptane derivative (0.40 mmol) in dioxane (1.0 mL). After LC-MS indicated complete conversion (2h) the mixture is concentrated in vacuo. The 25 residue is repeatedly dissolved in a mixture of MeOH and EtOAc and concentrated in vacuo to give the respective deprotected product as a hydrochloride salt which is used without further purification.
Benzofuran-4-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1]hept-3-yl)methyl]-amide t-BuO H Received at IPONZ on 20-Mar-2012 65 prepared by deprotection of (lR,3S,4S)-3-{[(Benzofuran-4-carbonyl)-amino]-methyl}-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester. LC-MS (basic): tR = 0.83 min; [M+H]+ = 271.2.
Quinoline-8-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1]hept-3-yl)methyl]-5 amide prepared by deprotection of (lR,3S,4S)-3-{[(Quinoline-8-carbonyl)-amino]-methyl}-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester. LC-MS (basic): tR = 0.93 min; [M+H]+ = 282.2. 2,3-Dihydro-benzo[l,4]dioxine-5-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1] 10 hept-3-yl)methyl]-amide prepared by deprotection of (lR,3S,4S)-3-{[(2,3-Dihydro-benzo[l,4]dioxine-5-carbonyl)-amino]-methyl}-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester. LC-MS (basic): tR = 0.81 min; [M+H]+ = 289.2. 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1] 15 hept-3-yl)methyl]-amide prepared by deprotection of (lR,3S,4S)-3-{[(6-Methyl-imidazo[2,l-b]thiazole-5-carbonyl)-amino]-methyl}-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester. LC-MS (basic): tR = 0.69 min; [M+H]+ = 291.1. 2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1] 20 hept-3-yl)methyl]-amide prepared by deprotection of (lR,3S,4S)-3-{[(2-Ethyl-5-methyl-2H-pyrazole-3-carbonyl)-amino]-methyl}-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester. LC-MS (basic): tR = 0.69 min; [M+H]+ = 263.3.
B.3 Synthesis of 2-substituted (lR,3S,4S)-3-Aminomethyl-2-aza-25 bicyclo[2.2.1]heptane derivatives B.3.1 Synthesis of (lR,3S,4S)-3-[(2,2,2-Trifluoro-acetylamino)-methyl]-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester Ethyl trifluoroacetate (12.2 mmol, 1.30eq) is added to a solution of (lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (9.42 mmol, 30 l.OOeq) and DIPEA (14.1 mmol, 1.50eq) in THF (25 mL). After 50 min the mixture is concentrated in vacuo, diluted with TBME (100 mL) and washed twice with aq. citric acid Received at IPONZ on 20-Mar-2012 66 (5%) and water respectively. The organic layer is dried over MgS04 and concentrated in vacuo to give a crude product which is used without further purification. LC-MS (basic): tR = 0.95 min; [M+H]+ = 323.2.
B.3.2 Synthesis of N-[(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-2,2,2-5 trifluoro-acetamide (hydrochloride salt) A solution of HCI in dioxane (4 M, 40 mL) is added to a solution of (lR,3S,4S)-3-[(2,2,2-trifluoro-acetylamino)-methyl]-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (12.0 mmol) in dioxane (15 mL). After 3h the solvents are removed in vacuo to give the desired product as a brownish solid which is used without further purification in the 10 next step. LC-MS (basic): tR = 0.69 min; [M+H]+ = 223.2.
B.3.3 Synthesis of 2,2,2-Trifluoro-N-[(lR,3S,4S)-2-(5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-acetamide derivatives (general procedure) TBTU (1.70 mmol, l.leq) is added to a solution of the respective 5-phenyl-thiazole-4-carboxylic acid derivative (1.62 mmol, 1.05eq) and DIPEA (2.33 mmol, 1.5 eq) in DMF 15 (5.0 mL). The mixture is stirred for 10 min and treated with a solution of N-[(1R,3S,4S)-1-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-2,2,2-trifluoro-acetamide (1.55 mmol, l.Oeq) and DIPEA (3.87 mmol, 2.5eq) in DMF (5.0 mL). After 90 min the mixture is diluted with TBME (50 mL) and washed three times with an aq. NaOH solution (0.5 M, 50 mL each). The combined aq. layers are extracted twice with TBME (30 mL each). The organic layers 20 are combined, washed with water (3 x 30 mL) and brine (30 mL), dried over MgS04 and concentrated in vacuo to give a crude product which is used without further purification. 2,2,2-Trifluoro-N-[(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicy clo [2.2.1 ] hept-3-ylmethyl] -acetamide prepared by reaction of N-[(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-2,2,2-25 trifluoro-acetamide with 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid. LC-MS (basic): tR = 0.94 min; [M+H]+ = 438.0.
N-{(lR,3S,4S)-2-[5-(3-Chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-2,2,2-trifluoro-acetamide prepared by reaction of N-[(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-2,2,2-30 trifluoro-acetamide with 5-(3-Chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid. LC-MS (basic): tR = 0.95 min; [M+H]+ = 457.7.
Received at IPONZ on 20-Mar-2012 67 B.3.4 Synthesis of N-{(lR,3S,4S)-2-[2-Amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-2,2,2-trifluoro-acetamide TBTU (1.70 mmol, l.lOeq) is added to a solution of 2-amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid (1.62 mmol, 1.05eq), N-[(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-5 yl)methyl]-2,2,2-trifluoro-acetamide (1.55 mmol, l.Oeq) and DIPEA (5.41 mmol, 3.5eq) in DMF (10 mL). After 90 min the mixture is diluted with TBME (50 mL) and washed three times with an aq. NaOH solution (0.5 M, 50 mL each). The combined aq. layers are extracted twice with TBME (30 mL each). The organic layers are combined, washed with water (3 x 30 mL) and brine (30 mL), dried over MgS04 and concentrated in vacuo to give 10 a crude product which is used without further purification. LC-MS (basic): tR = 0.82 min; [M+H]+ = 442.9.
B.3.5 Synthesis of N-{(lR,3S,4S)-2-[2-Dimethylamino-5-phenyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-2,2,2-trifluoro-acetamide derivatives (general procedure) TBTU (2.13 mmol) and DIPEA (4.83 mmol) are added to a solution of the respective 5-phenyl-thiazole-4-carboxylic acid derivative (2.32 mmol) in MeCN (5.0 mL). The mixture is stirred for 15 min and treated with a solution of N-[(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-2,2,2-trifluoro-acetamide (1.93 mmol) and DIPEA (4.83 mmol) in MeCN (5.0 mL). After 14h the mixture is diluted with EtOAc and washed three 20 times with brine. The combined aq. layers are extracted with EtOAc. The organic layers are combined, dried over MgS04 and concentrated in vacuo to give the respective crude product which is used without further purification.
N-{(lR,3S,4S)-2-[2-Dimethylamino-5-phenyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-2,2,2-trifluoro-acetamide prepared by reaction of N-[(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-2,2,2-trifluoro-acetamide with 2-dimethylamino-5-phenyl-thiazole-4-carboxylic acid. LC-MS: tR= 1.10 min; [M+H]+= 453.1.
N-{(lR,3S,4S)-2-[2-Dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-2,2,2-trifluoro-acetamide prepared by reaction of N-[(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-2,2,2-trifluoro-acetamide with 2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid. LC-MS: tR= 1.12 min; [M+H]+= 471.1.
Received at IPONZ on 20-Mar-2012 68 B.3.6 Synthesis of ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-[5-phenyl-thiazol-4-yl]-methanone derivatives (general procedure) A solution of the respective 2,2,2-trifluoro-N-[(lR,3S,4S)-2-(5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-acetamide derivative (1.49 mmol) in 5 MeOH (5.0 mL) is treated with a sat. aq. K2CO3 solution (0.4 mL) and stirred at 60°C for 6h. After stirring at rt for additional 14h the mixture is concentrated in vacuo and the residue is made acidic by addition of aq. citric acid (5%). The aq. layer is washed three times with TBME, made basic by addition of aq. NaOH solution and extracted four times with DCM. The combined DCM-layers are dried over Na2S04 and concentrated in vacuo 10 to give the desired product which is used without further purification. ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone prepared by deprotection of 2,2,2-Trifluoro-N-[(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-acetamide. LC-MS (basic): tR = 0.77 15 min; [M+H]+ = 342.1. ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl] -methanone prepared by deprotection of N-{(lR,3S,4S)-2-[5-(3-Chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-2,2,2-trifluoro-acetamide. LC-MS (basic): 20 tR = 0.79 min; [M+H]+ = 361.7.
B.3.7 Synthesis of [2-Amino-5-(3-fluoro-phenyl)-thiazol-4-yl]-((lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-methanone A solution of N-{(lR,3S,4S)-2-[2-Amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-2,2,2-trifluoro-acetamide (0.98 mmol) in MeOH (3.2 mL) 25 is treated with a sat. aq. K2CO3 solution (0.3 mL) and stirred at 60°C for 6h. After stirring at rt for additional 14h the mixture is concentrated in vacuo and the residue is made basic by addition of aq. NaOH solution. A 1:1 mixture of TBME and EtOAc is added and the mixture is stirred vigorously for lh. The layers are separated and the aq. layer is extracted with a 1:1 mixture of TBME and EtOAc. The combined organic layers are dried over 30 Na2S04 and concentrated in vacuo to give the desired product which is used without further purification. LC-MS (basic): tR = 0.68 min; [M+H]+ = 347.1.
Received at IPONZ on 20-Mar-2012 69 B.3.8 Synthesis of ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-[ 2-dimethylamino-5-phenyl-thiazol-4-yl]-methanone derivatives (general procedure) A solution of the respective 2,2,2-trifluoro-N-[(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2. l]hept-3-ylmethyl]-acetamide derivative (2.49 5 mmol) in isopropanol (30 mL) is treated with an aq. NaOH solution (1.0 M, 8.0 mL) and stirred for 3h. Water and EtOAc are added, the layers are separated and the aq. layer is extracted with EtOAc. The combined organic layers are washed with water, dried over MgS04 and concentrated in vacuo to give the desired product which is used without further purification. ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-(2-dimethylamino-5-phenyl-thiazol-4-yl)-methanone prepared by deprotection of N-{(lR,3S,4S)-2-[2-Dimethylamino-5-phenyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-2,2,2-trifluoro-acetamide. LC-MS: tR = 0.80 min; [M+H]+= 357.1. ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazol-4-yl]-methanone prepared by deprotection of N-{(lR,3S,4S)-2-[2-Dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-2,2,2-trifluoro-acetamide. LC-MS: tR = 0.81 min; [M+H]+ = 375.1.
B.4 Synthesis of [(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-(5-bromo-pyrimidin-2-yl)-amine B.4.1 Synthesis of (lR,3S,4S)-3-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester -Bromo-2-chloro-pyrimidine (8.62 mmol) is added to a solution of (lR,3S,4S)-3-25 aminomethyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (6.63 mmol) in o-xylene (25 mL). K2CO3 (20.0 mmol) and DIPEA (19.9 mmol) are added successively and the mixture is heated to 138°C for 16h. The mixture is cooled to rt and filtered. The residue is washed with DCM and the combined filtrates are concentrated in vacuo to give the desired product which is used without further purification. LC-MS: tR = 1.09 min; 30 [M+H]+ = 383.3.
Received at IPONZ on 20-Mar-2012 70 B.4.2 Synthesis of [(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-(5-bromo-pyrimidin-2-yl)-amine A solution of HCI in dioxane (4.0 M, 30 mL) is added to a solution of (lR,3S,4S)-3-[(5-bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.l]heptane-2-carboxylic acid tert-5 butyl ester (6.63 mmol) in dioxane (30 mL). After 4h the solvents are removed in vacuo to give a crude product which is used without further purification. LC-MS: tR = 0.64 min; [M+H]+ = 283.0.
C. Preparation of compounds of formula (I): C.l Synthesis of carboxylic amide derivatives (general procedure) Arik' — <^3$° H A B To a solution of the respective carboxylic acid (0.030 mmol, 1.2eq) in DMF (0.50 mL) is added successively DIPEA (0.025 mmol, l.Oeq) and a solution of TBTU (0.030 mmol, 1.2eq) in DMF (0.50 mL). The obtained mixture is treated with a solution of the respective 15 2-aza-bicyclo[2.2.1]heptane derivative (0.025 mmol, l.Oeq, hydrochloride salt) and DIPEA (0.050 mmol, 2.0eq) in DMF (0.50 mL). The mixture is shaken over night and purified by prep. HPLC to give the respective amide derivative.
Starting from Quinoline-8-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1]hept-3-yl)m ethyl]-amide: Example Name LC-MS eluent tR [min] [M+H]+ 1 Quinoline-8-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide basic 0.96 517.0 2 Quinoline-8-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.80 0.83 502.1 Received at IPONZ on 20-Mar-2012 71 3 Quinoline-8-carboxylic acid [(lR,3S,4S)-2-(2- basic 0.89 497.1 methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza- 0.95 bicyclo[2.2.1]hept-3-ylmethyl]-amide Starting from 2,3-Dihydro-benzo[l,4]dioxine-5-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1 ]hept-3 -yl)methyl] -amide: Example Name LC-MS eluent tR [min] [M+H]+ 4 2,3-Dihydro-benzo[l,4]dioxine-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.87 0.93 523.9 2,3-Dihydro-benzo[l,4]dioxine-5-carboxylic acid {('1 R,3 S ,4S)-2- [2-amino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.77 0.80 509.0 6 2,3-Dihydro-benzo[l,4]dioxine-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.85 0.92 504.1 Starting from Benzofuran-4-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1]hept-3-yl)methyl]-amide: Example Name LC-MS eluent tR [min] [M+H]+ 7 Benzofuran-4-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide basic 0.96 506.0 8 Benzofuran-4-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.79 0.83 490.7 Received at IPONZ on 20-Mar-2012 72 9 Benzofuran-4-carboxylic acid [(lR,3S,4S)-2-(2- methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza- bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.95 486.1 Benzofuran-4-carboxylic acid [(lR,3S,4S)-2-(3'- chloro-biphenyl-2-carbonyl)-2-aza- bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.98 485.0 11 Benzofuran-4-carboxylic acid [(lR,3S,4S)-2-(2- methyl-4-phenyl-pyrimidine-5-carbonyl)-2-aza- bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.79 0.83 467.1 Starting from 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1 ]hept-3 -yl)methyl] -amide: Example Name LC-MS eluent tR [min] [M+H]+ 12 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.88 525.9 13 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {('1 R,3 S ,4S)-2- [2-amino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.71 0.75 511.0 14 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.86 506.0 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(biphenyl-2-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.87 471.1 Received at IPONZ on 20-Mar-2012 73 16 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(3'-chloro-biphenyl-2-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide basic 0.90 504.9 17 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-4-phenyl-pyrimidine-5-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.69 0.74 487.0 18 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(3 -fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.86 0.91 509.9 19 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.85 0.90 509.9 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 0.87 0.92 506.0 21 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3,5-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.90 0.96 520.0 22 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(2,3-dichloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.97 559.8 23 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-bromo-4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.91 0.95 587.7 Received at IPONZ on 20-Mar-2012 74 24 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3,4-difluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.88 0.92 527.9 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-fluoro-2-methyl-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.93 523.9 26 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(3,4-dichloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.94 0.98 559.8 27 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.90 0.96 520.0 28 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 0.85 0.92 521.0 29 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.88 0.95 538.9 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 0.84 0.89 492.0 31 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 0.89 0.96 518.0 Received at IPONZ on 20-Mar-2012 75 32 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide acidic 0.87 0.90 512.4 33 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(3 -trifluorom ethyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.90 0.93 545.9 34 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(3 -methoxy-phenyl)-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide acidic 0.83 0.88 507.9 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(4-fluoro-phenyl)-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide acidic 0.83 0.87 495.9 36 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(2-fluoro-phenyl)-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide acidic 0.87 495.9 37 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-fluoro-4-methyl-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.89 0.94 523.9 Received at IPONZ on 20-Mar-2012 76 Starting from 2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid [(lR,3S,4S)-l-(2-aza-bicyclo[2.2.1 ]hept-3 -yl)methyl] -amide: Example Name LC-MS eluent tR [min] [M+H]+ 38 2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.92 498.1 39 2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid {('1 R,3 S ,4S)-2- [2-amino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.78 483.0 40 2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid [(lR,3S,4S)-2-(biphenyl-2-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.82 0.91 443.1 41 2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid [(lR,3S,4S)-2-(3'-chloro-biphenyl-2-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide basic 0.94 477.1 Starting from [(lR,3S,4S)-l-(2-Aza-bicyclo[2.2.1]hept-3-yl)methyl]-(5-bromo-pyrimidin-5 2-yl)-amine: Example Name LC-MS eluent tR [min] [M+H]+ 42 {(lR,3S,4S)-3-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.1]hept-2-yl} -(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone acidic 1.03 1.10 497.9 43 [5-(3-Bromo-4-fluoro-phenyl)-2-methyl-thiazol-4-yl] - {(lR,3S,4S)-3-[(5 -bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.1]hept-2-yl}-methanone acidic 1.07 1.12 580.7 Received at IPONZ on 20-Mar-2012 77 44 {(lR,3S,4S)-3-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.1]hept-2-yl}-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazol-4-yl]-methanone acidic 1.06 1.13 511.5 45 {(lR,3S,4S)-3-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.1]hept-2-yl} - [2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazol-4-yl]-methanone acidic 1.03 1.11 530.8 46 {(lR,3S,4S)-3-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.1]hept-2-yl} -(2-methyl-5-phenyl-thiazol-4-yl)-methanone acidic 1.00 1.06 483.8 47 {(lR,3S,4S)-3-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.1]hept-2-yl} -(2-cyclopropyl-5-phenyl-thiazol-4-yl)-methanone acidic 1.05 1.12 509.9 48 {(lR,3S,4S)-3-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.1]hept-2-yl}-[5-(3-chloro-phenyl)-thiazol-4-yl]-methanone acidic 1.04 1.08 503.8 49 {(lR,3S,4S)-3-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-2-aza-bicyclo[2.2.1]hept-2-yl}-[5-(3-fluoro-4-methyl-phenyl)-2-methyl-thiazol-4-yl]-methanone acidic 1.06 1.11 515.8 C.2 Synthesis of carboxylic amide derivatives (general procedure II) A 0 N NH2 ► A^° B B To a solution of the respective carboxylic acid (0.030 mmol, 1.2eq) in DMF (0.50 mL) is added successively DIPEA (0.025 mmol, l.Oeq) and a solution of TBTU (0.030 mmol, 1.2eq) in DMF (0.50 mL). The obtained mixture is treated with a solution of the respective 2-aza-bicyclo[2.2.1]heptane derivative (0.025 mmol, l.Oeq) and DIPEA (0.050 mmol, Received at IPONZ on 20-Mar-2012 78 2.0eq) in DMF (0.50 mL). The mixture is shaken over night and purified by prep. HPLC to give the respective amide derivative.
Starting from ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone: Example Name LC-MS eluent tR [min] [M+H]+ 50 2,3-Dihydro-thieno[3,4-b][l,4]dioxine-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.84 0.90 509.9 51 2-Bromo-thiazole-4-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide basic 0.94 530.8 52 2,3,6,7-Tetrahydro-benzo[l,2-b;4,5-b']difuran-4-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide basic 0.96 530.0 Starting from ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-[5-(3-chloro-phenyl)-2-methyl-thiazol-4-yl]-methanone: Example Name LC-MS eluent tR [min] [M+H]+ 53 2,3-Dihydro-thieno[3,4-b][l,4]dioxine-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.91 529.9 54 2-Bromo-thiazole-4-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(3 -chloro-phenyl)-2-methyl-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide basic 0.95 550.6 Received at IPONZ on 20-Mar-2012 79 55 6-Methoxy-pyridine-2-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(3 -chloro-phenyl)-2-methyl-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide basic 0.97 496.9 56 2,3,6,7-Tetrahydro-benzo[l,2-b;4,5-b']difuran-4-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.98 549.9 Starting from [2-Amino-5-(3-fluoro-phenyl)-thiazol-4-yl]-((lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-methanone: Example Name LC-MS eluent tR [min] [M+H]+ 57 2,3-Dihydro-thieno[3,4-b][l,4]dioxine-5-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.76 0.80 514.9 58 2-Bromo-thiazole-4-carboxylic acid {(1 R,3 S ,4S)-2- [2-amino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide basic 0.82 535.7 59 6-Methoxy-pyridine-2-carboxylic acid {(1 R,3 S ,4S)-2- [2-amino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide basic 0.80 0.83 481.9 60 3,4-Dihydro-2H-benzo[l,4]oxazine-5-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide basic 0.81 0.85 507.9 Received at IPONZ on 20-Mar-2012 80 61 2,3,6,7-Tetrahydro-benzo[l,2-b;4,5-b']difuran- basic 0.82 535.0 4-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3- 0.84 fluoro-phenyl)-thiazole-4-carbonyl]-2-aza- bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide C.3 Synthesis of carboxylic amide derivatives (general procedure III) A 0 n nhs —- r1 af0 A^° B B To a solution of the respective carboxylic acid (0.13 mmol, l.Oeq) in MeCN (1.0 mL) is 5 added TBTU (0.15 mmol, 1.1 eq). DIPEA (0.33 mmol) is added and the mixture is stirred for 15 min. The obtained mixture is treated with a solution of the respective 2-aza-bicyclo[2.2.1]heptane derivative (0.13 mmol, l.Oeq) and DIPEA (0.33 mmol) in MeCN (1.0 mL). The mixture is shaken over night and purified by prep. HPLC to give the respective amide derivative.
Starting from ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-(2- dimethylamino-5-phenyl-thiazol-4-yl)-methanone: Example Name LC-MS eluent tR [min] [M+H]+ 62 1-Methyl-lH-benzoimidazole-2-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 1.00 1.09 515.7 63 l-Methyl-lH-indazole-3-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 0.98 1.09 515.7 64 Imidazo[l,2-a]pyridine-3-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 0.78 0.87 501.1 Received at IPONZ on 20-Mar-2012 81 65 3-Methyl-lH-indene-2-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 1.06 1.17 513.3 66 2-Methyl-benzooxazole-4-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 1.00 1.10 516.6 67 Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide acidic 0.90 1.05 518.5 68 6-Methyl-pyrrolo[2,l-b]thiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide acidic 0.91 1.05 520.4 Starting from ((lR,3S,4S)-3-Aminomethyl-2-aza-bicyclo[2.2.1]hept-2-yl)-[2- dimethylamino-5-(3-fluoro-phenyl)-thiazol-4-yl]-methanone: Example Name LC-MS eluent tR [min] [M+H]+ 69 1-Methyl-lH-benzoimidazole-2-carboxylic acid {(1 R,3 S ,4S)-2- [2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 1.04 1.12 533.5 70 lH-Indazole-3-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide acidic 0.96 1.06 519.4 Received at IPONZ on 20-Mar-2012 82 71 Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide acidic 0.94 1.08 536.4 72 l-Methyl-lH-indazole-3-carboxylic acid {(1 R,3 S ,4S)-2- [2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 1.03 1.12 533.5 73 1,2-Dim ethyl-lH-indole-3-carboxylic acid {(1 R,3 S ,4S)-2- [2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 1.02 1.13 546.5 74 lH-Indole-3-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl}-amide acidic 0.93 1.05 518.4 75 Benzo[d]isoxazole-3-carboxylic acid {(1 R,3 S ,4S)-2- [2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 1.03 1.14 520.6 76 3-Methyl-lH-indene-2-carboxylic acid {(1 R,3 S ,4S)-2- [2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 1.10 1.19 531.5 77 -Fluoro-l-methyl-lH-indole-2-carboxylic acid {(1 R,3 S ,4S)-2- [2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 1.10 1.20 550.6 78 l,2-Dimethyl-lH-benzoimidazole-5-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide acidic 0.76 0.87 547.6 Received at IPONZ on 20-Mar-2012 83 79 2-Methyl-benzooxazole-4-carboxylic acid acidic 1.04 534.4 {(1 R,3 S ,4S)-2- [2-dimethylamino-5 -(3 -fluoro- 1.13 phenyl)-thiazole-4-carbonyl]-2-aza- bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide The following examples were prepared according to the methods described above by selecting the most appropriate methodology and pathway and combining the respective building blocks (LC-MS-data were recorded under acidic conditions): Example 80: Benzothiazole-7-carboxylic acid {(R,S,S)-2-[5-(3-chloro-phenyl)-2-methoxy-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.14 min; [M+H]+ = 539.03.
Example 81: Benzothiazole-7-carboxylic acid {(R,S,S)-2-[5-(3-chloro-phenyl)-2-ethoxy-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.18 min; [M+H]+ = 553.27.
Example 82: Benzothiazole-7-carboxylic acid {(R,S,S)-2-[5-(3-chloro-phenyl)-2-(2-methoxy-ethoxy)-15 thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.13 min; [M+H]+ = 583.00.
Example 83: Benzothiazole-7-carboxylic acid {(R,S,S)-[2-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]}-amide; LC-MS: tR = 1.11 min; [M+H]+ = 20 515.37.
Example 84: Benzothiazole-7-carboxylic acid {(R,R,S)-2-[2-cyclopropyl-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.12 min; [M+H]+ = 533.5.
Example 85: Benzothiazole-7-carboxylic acid {(R,R,S)-2-[2-methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.11 min; [M+H]+ = 557.43.
Received at IPONZ on 20-Mar-2012 84 Example 86: Benzothiazole-7-carboxylic acid {(R,R,S)-2-[2-dimethylamino-5-(3,4-dimethyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.12 min; [M+H]+ = 546.46.
Example 87: Benzothiazole-7-carboxylic acid {(R,R,S)-2-[5-(3-chloro-phenyl)-2-dimethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.13 min; [M+H]+ = 552.05.
Example 88: Benzothiazole-7-carboxylic acid {(R,R,S)-2-[5-(3-chloro-phenyl)-2-(ethyl-methyl-amino)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.19 min; [M+H]+ = 566.27.
Example 89: Benzothiazole-7-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(3 -chloro-phenyl)-2-diethylamino-15 thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.25 min; [M+H]+ = 580.22.
Example 90: Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(3-p-tolyl-pyrazine-2-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; LC-MS: tR = 0.97 min; [M+H]+ = 484.51. 20 Example 91: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(4-methoxy-phenyl)-thiophene-2-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.06 min; [M+H]+ = 504.41.
Example 92: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(3-methoxy-phenyl)-thiophene-2-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.06 min; [M+H]+ = 504.48.
Example 93: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(3,4-dimethoxy-phenyl)-thiophene-2-30 carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.00 min; [M+H]+ = 534.55.
Received at IPONZ on 20-Mar-2012 85 Example 94: Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(3-benzo[l,3]dioxol-5-yl-thiophene-2-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; LC-MS: tR = 1.04 min; [M+H]+ = 518.35.
Example 95: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(2-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.07 min; [M+H]+ = 536.55.
Example 96: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.07 min; [M+H]+ = 536.47.
Example 97: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-methoxy-phenyl)-15 thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.06 min; [M+H]+ = 548.33.
Example 98: Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-cyclopropyl-5-p-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; LC-MS: tR = 1.18 min; [M+H]+ = 20 529.34.
Example 99: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-cyclopropyl-5-(2-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.13 min; [M+H]+ = 533.50.
Example 100: Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-cyclopropyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; LC-MS: tR = 1.17 min; [M+H]+ = 529.60.
Example 101: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-cyclopropyl-5-(3-fluoro-4-methyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.19 min; [M+H]+= 547.57.
Received at IPONZ on 20-Mar-2012 86 Example 102: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.02 min; [M+H]+ = 538.20.
Example 103: Benzothiazole-7-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(3 -chloro-phenyl)-2-ethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.07 min; [M+H]+ = 552.20.
Example 104: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-methyl-5-(3-trifluoromethoxy-phenyl)-oxazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.13 min; [M+H]+ = 557.13.
Example 105: Benzo[d]isothiazole-3-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-15 phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.12 min; [M+H]+= 536.20.
Example 106: -Ethyl-3-methyl-isoxazole-4-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: 20 tR= 1.06 min; [M+H]+ = 511.80.
Example 107: 3-Ethyl-5-methyl-isoxazole-4-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.05 min; [M+H]+ = 511.86.
Example 108: Quinoxaline-5-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.05 min; [M+H]+ = 531.11.
Example 109: Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(lH-indol-6-yl)-pyrazine-2-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 0.95 min; [M+H]+ = 509.17.
Received at IPONZ on 20-Mar-2012 87 Example 110: Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[5-(2-fluoro-phenyl)-2-pyrrolidin-l-yl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.12 min; [M+H]+ = 562.69.
Example 111: Benzothiazole-7-carboxylic acid [(1 S,3R,4R)-2-(2-dimethylamino-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; LC-MS: tR = 1.11 min; [M+H]+ = 532.58.
Example 112: Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[2-(ethyl-methyl-amino)-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.12 min; [M+H]+= 562.24.
Example 113: Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[5-(3-bromo-4-fluoro-phenyl)-2-15 dimethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR= 1.15 min; [M+H]+= 616.13.
Example 114: Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[5-(4-fluoro-phenyl)-2-pyrrolidin-l-yl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.11 min; 20 [M+H]+ = 562.49.
Example 115: Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-dimethylamino-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.07 min; [M+H]+ = 536.13.
Example 116: Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-diethylamino-5-(2-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.19 min; [M+H]+ = 564.73.
Example 117: Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[2-dimethylamino-5-(3-fluoro-4-methyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.14 min; [M+H]+= 550.64.
Received at IPONZ on 20-Mar-2012 88 Example 118: Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-(ethyl-methyl-amino)-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.13 min; [M+H]+= 550.63.
Example 119: Benzothiazole-7-carboxylic acid [(1 S,3R,4R)-2-(2-dimethylamino-5-p-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; LC-MS: tR = 1.11 min; [M+H]+ = 532.62.
Example 120: Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[2-dimethylamino-5-(3-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.15 min; [M+H]+= 586.60.
Example 121: Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-diethylamino-5-(4-fluoro-phenyl)-15 thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; LC-MS: tR = 1.18 min; [M+H]+ = 564.51.
Received at IPONZ on 20-Mar-2012 89 II-Biological assays In vitro assay Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-5 Glutamine) containing 300 jj,g/ml G418, 100 U/ml penicillin, 100 jj,g/ml streptomycin and 10 % heat inactivated fetal calf serum (FCS). The cells are seeded at 20'000 cells / well into 384-well black clear bottom sterile plates (Greiner). The seeded plates are incubated overnight at 37°C in 5% CO2.
Human orexin-A as an agonist is prepared as 1 mM stock solution in MeOH: water (1:1), 10 diluted in HBSS containing 0.1 % bovine serum albumin (BSA), NaHC03: 0.375g/l and 20 mM HEPES for use in the assay at a final concentration of 3 nM.
Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 384-well plates, first in DMSO, then in HBSS containing 0.1 % bovine serum albumin (BSA), NaHC03: 0.375g/l and 20 mM HEPES.
On the day of the assay, 50 jj.1 of staining buffer (HBSS containing 1% FCS, 20 mM HEPES, NaHCOs: 0.375g/l, 5 mM probenecid (Sigma) and 3 jj,M of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well.
The 384-well cell-plates are incubated for 50 min at 37° C in 5% CO2 followed by 20 equilibration at rt for 30 - 120 min before measurement.
Within the Fluorescent Imaging Plate Reader (FLIPR2 or FLIPR Tetra, Molecular Devices), antagonists are added to the plate in a volume of 10 jjl/well, incubated for 10 min and finally 10 jjl/well of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the 25 fluorescence peak induced by 3 nM orexin-A with vehicle in place of antagonist. For each antagonist, the IC50 value (the concentration of compound needed to inhibit 50 % of the agonistic response) is determined. Optimized conditions may be achieved by adjustment of pipetting speed and cell splitting regime. The calculated IC50 values of the compounds may fluctuate depending on the daily cellular assay performance. Fluctuations of this kind are 30 known to those skilled in the art.
Antagonistic activities (IC50 values) of all exemplified compounds are below 1000 nM with respect to the OXi and/or the OX2 receptor. Antagonistic activities (IC50 values) of

Claims (17)

1.Received at IPONZ on 20-Mar-2012 90 116 exemplified compounds are in the range of 6-8916 nM with an average of 730 nM with respect to the 0X1 receptor (5 compounds have been measured with an IC50 value >10000 nM). IC50 values of 118 exemplified compounds are in the range of 10-9479 nM with an average of 469 nM with respect to the OX2 receptor(3 compounds have been measured with an IC50 value >10000 nM). Antagonistic activities of selected compounds are displayed in Table 1. Table 1 Compound of Example OXi IC50 (nM) OX2 IC50 (nM) 1 59 622 5 149 29 11 75 2135 31 138* 55* 35 278* 808* 40 >10000 441 46 488* 364* 63 307* 61* 79 64* 1} 71 * ^ 80 80* 15* 94 1269* 81* 97 12* 1} 14* 1} 104 305* 37* 105 65* 421* 109 707* 19* 110 23* 30* 118 117* 32* IC50 values measured with FLIPR 2 or, if marked with *, with FLIPR Tetra; 1> geometric mean from n=2 values; Received at IPONZ on 20-Mar-2012 91 Claims 1) A compound of formula (I) wherein the stereogenic centers are in absolute (1R,3S,4S)-configuration A represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (c3-6)cycloalkyl, (c2-6)alkinyl, (Ci_4)alkoxy, 10 NR2R3, halogen, (Ci_4)alkoxy-(Ci_4)alkoxy, and unsubstituted or independently mono- or di-substituted phenyl or pyridyl, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, fluorine and chlorine; B represents an aryl- or heterocyclyl-group, wherein the aryl or heterocyclyl is 15 unsubstituted or independently mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, -NR4R5, -NHS02-(Ci_4)alkyl, -N(R4)C(0)R5 and halogen; or B represents a benzo[l,3]dioxolyl group. n represents the integer 0 or 1; 20 R1 represents heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, halogen, trifluoromethyl and -NR4R5; or R1 represents a lH-indenyl, a 2,3-dihydro-benzofuranyl-, a benzo[l,3]dioxolyl-, a 2,3-dihydro-benzo[l,4]dioxinyl-, a 4//-bcnzo[ 1,3]dioxinyi-, a 2//-chromcnyl-, a chromanyl-, a 25 2,3-dihydro-thieno[3,4-b][l,4]dioxinyl-, a 3,4-dihydro-2//-bcnzo[ 1,4]oxazinyl- or a 2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuranyl-group; wherein said groups are \ 5 B Formula (I) wherein Received at IPONZ on 20-Mar-2012 92 unsubstituted, mono- or di-substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen; R2 represents hydrogen or (Ci_4)alkyl; R3 represents hydrogen or (Ci_4)alkyl; 5 or R2 and R3 together with the nitrogen to which they are attached to form a pyrrolidine ring; R4 represents hydrogen or (Ci_4)alkyl; and R5 represents hydrogen or (Ci_4)alkyl; wherein the term "heterocyclyl" means a 5- to 10-membered monocyclic or bicyclic 10 aromatic ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur; or a pharmaceutically acceptable salt of such a compound.
2. A compound of formula (I) according to claim 1, which is also a compound of Formula (Ip), wherein the stereogenic centers are in absolute (lR,3S,4S)-configuration 15 B Formula (Ip) wherein A represents aryl or heterocyclyl, wherein the aryl or heterocyclyl is unsubstituted or independently mono- or di-substituted, wherein the substituents are independently selected 20 from the group consisting of (Ci_4)alkyl, (C3-6)cycloalkyl, (C2-6)alkinyl, (Ci_4)alkoxy, NR2R3, halogen, and unsubstituted or independently mono- or di-substituted phenyl or pyridyl, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, trifluoromethoxy, fluorine and chlorine; B represents an aryl- or heterocyclyl-group, wherein the aryl or heterocyclyl is 25 unsubstituted or independently mono-, di-, or tri-substituted, wherein the substituents are Received at IPONZ on 20-Mar-2012 93 independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl, -NR4R5, -NHS02-(Ci_4)alkyl, -N(R4)C(0)R5 and halogen; n represents the integer 0 or 1; R1 represents heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di-, or tri-5 substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, halogen, trifluoromethyl and -NR4R5; or R1 represents a lH-indenyl, a 2,3-dihydro-benzofuranyl-, a benzo[l,3]dioxolyl-, a 2,3-dihydro-benzo[l,4]dioxinyl-, a 4//-benzo[l,3]dioxinyl-, a 2//-chromenyl-, a chromanyl-, a 2,3-dihydro-thieno[3,4-b][l,4]dioxinyl-, a 3,4-dihydro-2//-benzo[l,4]oxazinyl- or a 10 2,3,6,7-tetrahydro-benzo[l,2-b;4,5-b']difuranyl-group; wherein said groups are unsubstituted, mono- or di-substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen; R2 represents hydrogen or (Ci_4)alkyl; and R3 represents hydrogen or (Ci_4)alkyl; 15 R4 represents hydrogen or (Ci_4)alkyl; and R5 represents hydrogen or (Ci.4)alkyl; or a pharmaceutically acceptable salt of such a compound.
3. A compound according to claims 1 or 2, wherein n represents the integer 1; or a pharmaceutically acceptable salt of such a compound. 20
4. A compound according to any one of claims 1 to 3, wherein A represents phenyl or 5- to 6-membered monocyclic heterocyclyl, wherein the phenyl or heterocyclyl is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (C3.6)cycloalkyl, (Ci_4)alkoxy, NR2R3 and halogen; 25 or a pharmaceutically acceptable salt of such a compound.
5. A compound according to any one of claims 1 to 4, wherein B represents aryl, wherein the aryl is unsubstituted or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy, trifluoromethyl and halogen; 30 or a pharmaceutically acceptable salt of such a compound.
6. A compound according to any one of claims 1 to 5, wherein Received at IPONZ on 20-Mar-2012 94 R1 represents heterocyclyl, wherein the heterocyclyl is unsubstituted or independently mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen; or R1 represents a lH-indenyl, a 2,3-dihydro-benzo[l,4]dioxinyl-, a 2,3-dihydro-thieno[3,4-b] 5 [l,4]dioxinyl-, a 3,4-dihydro-2//-benzo[l,4]oxazinyl- or a 2,3,6,7-tetrahydro-benzo[l,2-b; 4,5-b']difuranyl-group, wherein said groups are unsubstituted or mono- or di-substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci_4)alkoxy and halogen; or a pharmaceutically acceptable salt of such a compound. 10
7. A compound according to any one of claims 1 to 6, wherein A represents 5- to 6-membered monocyclic heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-substituted wherein the substituent is selected from the group consisting of (Ci_4)alkyl, (C3.6)cycloalkyl and NR2R3; or a pharmaceutically acceptable salt of such a compound. 15
8. A compound according to any one of claims 1 to 7, wherein, in case R1 represents heterocyclyl, said heterocyclyl is selected from isoxazolyl, thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, pyrrolo[2,l-b]thiazolyl, imidazo[l,2-a]pyridyl and imidazo[2,l-20 b]thiazolyl, wherein said heterocyclyl is unsubstituted or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci_ 4)alkyl, (Ci_4)alkoxy and halogen; or a pharmaceutically acceptable salt of such a compound.
9. A compound according to any one of claims 1 to 8 selected from the group consisting 25 of: Quinoline-8-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide; Quinoline-8-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide;0 30 2,3-Dihydro-benzo[l,4]dioxine-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Received at IPONZ on 20-Mar-2012 95 2,3-Dihydro-benzo[l,4]dioxine-5-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzofuran-4-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzofuran-4-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzofuran-4-carboxylic acid [(lR,3S,4S)-2-(2-methyl-4-phenyl-pyrimidine-5-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(biphenyl-2-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-bromo-4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-methyl-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid [(lR,3S,4S)-2-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Received at IPONZ on 20-Mar-2012 96 6-Methyl-imidazo[2,l-b]thiazole-5-carboxylic acid {(lR,3S,4S)-2-[5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 2,3,6,7-Tetrahydro-benzo[l,2-b;4,5-b']difuran-4-carboxylic acid {(lR,3S,4S)-2-[2-amino- 5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 5 1-Methyl-lH-benzoimidazole-2-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5- phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 1.-Methyl-lH-indazole-3-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 2.-Methyl-benzooxazole-4-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-10 thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 3.Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 6-Methyl-pyrrolo[2,l-b]thiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-dimethylamino-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 15 1-Methyl-lH-benzoimidazole-2-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 R,3 S ,4S)-2- [2-dimethylamino-5 -(3 -fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 1,2-Dimethyl-1 H-indole-3 -carboxylic acid {(1 R,3 S ,4S)-2-[2-dimethylamino-5 -(3 -fluoro-20 phenyl)-thiazole- 4.-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 5.-Fluoro-l-methyl-lH-indole-2-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 2-Methyl-benzooxazole-4-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 25 Benzothiazole-7-carboxylic acid {(R,S,S)-2-[5-(3-chloro-phenyl)-2-methoxy-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,S,S)-2-[5-(3-chloro-phenyl)-2-ethoxy-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,S,S)-2-[5-(3-chloro-phenyl)-2-(2-methoxy-ethoxy)-3 0 thiazole-4-carbonyl] -2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide; Benzothiazole-7-carboxylic acid {(R,S,S)-[2-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]}-amide; Received at IPONZ on 20-Mar-2012 97 Benzothiazole-7-carboxylic acid {(R,R,S)-2-[2-cyclopropyl-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,R,S)-2-[2-methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 5 Benzothiazole-7-carboxylic acid {(R,R,S)-2-[2-dimethylamino-5-(3,4-dimethyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,R,S)-2-[5-(3-chloro-phenyl)-2-dimethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(R,R,S)-2-[5-(3-chloro-phenyl)-2-(ethyl-methyl-amino)-10 thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-diethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(3-p-tolyl-pyrazine-2-carbonyl)-2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl] -amide; 15 Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(4-methoxy-phenyl)-thiophene-2-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(3-methoxy-phenyl)-thiophene-2-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[3-(3,4-dimethoxy-phenyl)-thiophene-2-20 carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(3-benzo[l,3]dioxol-5-yl-thiophene-2-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(2-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 25 Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-cyclopropyl-5-p-tolyl-thiazole-4-30 carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-cyclopropyl-5-(2-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Received at IPONZ on 20-Mar-2012 98 Benzothiazole-7-carboxylic acid [(lR,3S,4S)-2-(2-cyclopropyl-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[2-cyclopropyl-5-(3-fluoro-4-methyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 5 Benzothiazole-7-carboxylic acid {(lR,3S,4S)-2-[5-(3-chloro-phenyl)-2-methylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 R,3 S ,4S)-2- [5 -(3 -chloro-phenyl)-2-ethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 R,3 S ,4S)-2- [2-methyl-5 -(3 -trifluoromethoxy-phenyl)-10 oxazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzo[d]isothiazole-3-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 5-Ethyl-3-methyl-isoxazole-4-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 15 3-Ethyl-5-methyl-isoxazole-4-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Quinoxaline-5-carboxylic acid {(lR,3S,4S)-2-[2-dimethylamino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 R,3 S ,4S)-2- [3 -(1 H-indol- 6.-yl)-pyrazine-2-carbonyl] -20 2-aza-bicyclo[2.2.1 ]hept-3 -ylmethyl} -amide; Benzothiazole- 7.-carboxylic acid {(lS,3R,4R)-2-[5-(2-fluoro-phenyl)-2-pyrrolidin-l-yl-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid [(1 S,3R,4R)-2-(2-dimethylamino-5-m-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; 25 Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[2-(ethyl-methyl-amino)-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[5-(3-bromo-4-fluoro-phenyl)-2-dimethylamino-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[5-(4-fluoro-phenyl)-2-pyrrolidin-l-yl-30 thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-dimethylamino-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Received at IPONZ on 20-Mar-2012 99 Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-diethylamino-5-(2-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-dimethylamino-5-(3-fluoro-4-methyl-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; 5 Benzothiazole-7-carboxylic acid {(lS,3R,4R)-2-[2-(ethyl-methyl-amino)-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; Benzothiazole-7-carboxylic acid [(1 S,3R,4R)-2-(2-dimethylamino-5-p-tolyl-thiazole-4-carbonyl)-2-aza-bicyclo[2.2.1]hept-3-ylmethyl]-amide; Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-dimethylamino-5-(3-trifluoromethyl-10 phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; and Benzothiazole-7-carboxylic acid {(1 S,3R,4R)-2-[2-diethylamino-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-2-aza-bicyclo[2.2.1]hept-3-ylmethyl}-amide; or a pharmaceutically acceptable salt of such a compound.
10. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable 15 salt thereof, for use as medicament.
11. A pharmaceutical composition containing, as active principle, a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient..
12. Use of a compound according to any of claims 1 to 9, or of a pharmaceutically 20 acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use and abuse, of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders. 25
13. Use according to claim 12 of a compound according to any of claims 1 to 9, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of all types of sleep disorders that comprises all types of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag 30 syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders. Received at IPONZ on 20-Mar-2012 100
14. A compound according to any of claims 1 to 9, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, for the prevention or treatment of diseases selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use and abuse, of cognitive 5 dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.
15. A compound of claim 1 or claim 14, substantially as herein described with reference to any example thereof.
16. A pharmaceutical composition of claim 11, substantially as herein described with 10 reference to any example thereof.
17. A use of claim 12, substantially as herein described with reference to any example thereof.
NZ588080A 2008-02-21 2009-02-19 2-Aza-bicyclo[2.2.1]heptane derivatives NZ588080A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008050622 2008-02-21
PCT/IB2009/050689 WO2009104155A1 (en) 2008-02-21 2009-02-19 2-aza-bicyclo[2.2.1]heptane derivatives

Publications (1)

Publication Number Publication Date
NZ588080A true NZ588080A (en) 2012-04-27

Family

ID=40626760

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ588080A NZ588080A (en) 2008-02-21 2009-02-19 2-Aza-bicyclo[2.2.1]heptane derivatives

Country Status (18)

Country Link
US (1) US8236801B2 (en)
EP (1) EP2247586B1 (en)
JP (1) JP2011512400A (en)
KR (1) KR20100119576A (en)
CN (1) CN101965343A (en)
AR (1) AR070459A1 (en)
AT (1) ATE555107T1 (en)
AU (1) AU2009215243A1 (en)
BR (1) BRPI0908096A2 (en)
CA (1) CA2713184A1 (en)
ES (1) ES2385699T3 (en)
IL (1) IL207685A0 (en)
MA (1) MA32151B1 (en)
MX (1) MX2010008993A (en)
NZ (1) NZ588080A (en)
RU (1) RU2010138640A (en)
WO (1) WO2009104155A1 (en)
ZA (1) ZA201006732B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504957A (en) * 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド 3-Aza-bicyclo [3.1.0] hexane derivatives
EP2094685B1 (en) 2006-12-01 2011-01-19 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors
AR064561A1 (en) * 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd DERIVATIVES OF 2-AZA-BICYCLE [3.1.0] HEXANE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO GENERAL DYSFUNCTIONS OF THE OREXINE SYSTEM.
CL2008000836A1 (en) * 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Thiazolidine derivative compounds, orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the treatment of emotional neurosis, severe depression, psychotic disorders, Alzheimer's, parkinson's, pain, among others.
KR20100046047A (en) * 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-aza-bicyclo[3.3.0]octane derivatives
CA2699328A1 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
JP2011519849A (en) * 2008-04-30 2011-07-14 アクテリオン ファーマシューティカルズ リミテッド Piperidine and pyrrolidine compounds
BRPI0920183A2 (en) * 2008-10-14 2018-05-22 Actelion Pharmaceuticals Ltd phenethylamide derivatives and their heterocyclic analogs
EP2275421A1 (en) * 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
AR079967A1 (en) 2010-01-26 2012-02-29 Sanofi Aventis 3-HETEROAROILAMINE-PROPIONIC ACID DERIVATIVES REPLACED WITH OXYGEN AND ITS USE AS PHARMACEUTICAL PRODUCTS
KR20140040104A (en) 2011-01-19 2014-04-02 갈라파고스 엔.브이. Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
JP5989112B2 (en) 2011-07-26 2016-09-07 サノフイ Substituted 3- (thiazole-4-carbonyl)-or 3- (thiazole-2-carbonyl) -aminopropionic acid derivatives and their use as medicaments
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
CN104220065A (en) * 2012-02-07 2014-12-17 Eolas治疗公司 Substituted prolines/piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
HUE031753T2 (en) * 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
TW201414727A (en) 2012-10-10 2014-04-16 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [orthobi(hetero-)aryl]-[2-(metabi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
TWI621618B (en) * 2013-03-13 2018-04-21 比利時商健生藥品公司 Substituted 2-azabicyclics and their use as orexin receptor modulators
TW201444821A (en) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv Substituted piperidine compounds and their use as orexin receptor modulators
TW201444849A (en) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators
UA119151C2 (en) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
AU2014358742B2 (en) 2013-12-03 2019-02-07 Idorsia Pharmaceuticals Ltd Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
JP6421185B2 (en) 2013-12-04 2018-11-07 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Use of benzimidazole-proline derivatives
MX2016011549A (en) * 2014-03-06 2017-05-08 Shanghai Haiyan Pharmaceutical Tech Co Ltd Piperidine derivatives as orexin receptor antagonist.
ES2901418T3 (en) 2014-08-13 2022-03-22 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
JP6715239B2 (en) * 2014-09-11 2020-07-01 ヤンセン ファーマシューティカ エヌ．ベー． Substituted 2-azabicyclic compounds and their use as orexin receptor modulators
WO2017028732A1 (en) * 2015-08-14 2017-02-23 上海海雁医药科技有限公司 Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
EA036542B9 (en) 2016-02-12 2020-12-22 Астразенека Аб Halo-substituted piperidines as orexin receptor modulators
CN111315734B (en) 2017-09-01 2024-03-08 克罗诺斯治疗有限公司 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
TW202400149A (en) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE293101T1 (en) 2000-06-16 2005-04-15 Smithkline Beecham Plc PIPERIDINE FOR USE AS OREXIN RECEPTOR ANTAGONISTS
EP1353918B1 (en) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
AU2002341123A1 (en) 2001-05-05 2002-11-18 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
EP1385845B1 (en) 2001-05-05 2008-01-09 Smithkline Beecham Plc N-aroyl cyclic amines
IL159041A0 (en) 2001-06-28 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
US20060014733A1 (en) 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
JP2009535324A (en) 2006-04-26 2009-10-01 アクテリオン ファーマシューティカルズ リミテッド Novel pyrazolo-tetrahydropyridine derivatives
CN101506199A (en) 2006-08-15 2009-08-12 埃科特莱茵药品有限公司 Azetidine compounds as orexin receptor antagonists
JP2010504957A (en) 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド 3-Aza-bicyclo [3.1.0] hexane derivatives
EP2094685B1 (en) 2006-12-01 2011-01-19 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors
AR064561A1 (en) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd DERIVATIVES OF 2-AZA-BICYCLE [3.1.0] HEXANE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO GENERAL DYSFUNCTIONS OF THE OREXINE SYSTEM.
CL2008000836A1 (en) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Thiazolidine derivative compounds, orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the treatment of emotional neurosis, severe depression, psychotic disorders, Alzheimer's, parkinson's, pain, among others.
EP2155739B1 (en) 2007-05-14 2010-10-06 Actelion Pharmaceuticals Ltd. 2-cyclopropyl-thiazole derivatives
PT2152690E (en) 2007-05-23 2012-03-30 Merck Sharp & Dohme Pyridyl piperidine orexin receptor antagonists
AU2008260647A1 (en) 2007-05-23 2008-12-11 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
BRPI0812981A2 (en) 2007-07-03 2014-12-16 Glaxo Group Ltd PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
EP2164847B1 (en) 2007-07-03 2011-09-14 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
AR067665A1 (en) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd DERIVATIVES OF TRANS-3- AZA-BICYCLE (3.1.0) HEXANO
KR20100046047A (en) 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-aza-bicyclo[3.3.0]octane derivatives
CA2699328A1 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
AU2008340421B2 (en) 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
JP2011519849A (en) 2008-04-30 2011-07-14 アクテリオン ファーマシューティカルズ リミテッド Piperidine and pyrrolidine compounds
CA2724648A1 (en) 2008-05-22 2009-11-26 Merck Sharp & Dohme Corp. Process for the preparation of an orexin receptor antagonist

Also Published As

Publication number Publication date
EP2247586B1 (en) 2012-04-25
BRPI0908096A2 (en) 2015-08-25
KR20100119576A (en) 2010-11-09
MX2010008993A (en) 2010-09-07
ES2385699T3 (en) 2012-07-30
IL207685A0 (en) 2010-12-30
US20110009401A1 (en) 2011-01-13
AU2009215243A1 (en) 2009-08-27
ATE555107T1 (en) 2012-05-15
ZA201006732B (en) 2012-03-28
EP2247586A1 (en) 2010-11-10
CA2713184A1 (en) 2009-08-27
MA32151B1 (en) 2011-03-01
JP2011512400A (en) 2011-04-21
US8236801B2 (en) 2012-08-07
AR070459A1 (en) 2010-04-07
RU2010138640A (en) 2012-03-27
WO2009104155A1 (en) 2009-08-27
CN101965343A (en) 2011-02-02

Similar Documents

Publication Publication Date Title
EP2247586B1 (en) 2-aza-bicyclo[2.2.1]heptane derivatives
EP2185512B1 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
EP2094690B1 (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
EP2155739B1 (en) 2-cyclopropyl-thiazole derivatives
US8106215B2 (en) 3-aza-bicyclo[3.3.0]octane compounds
US8063099B2 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2008038251A2 (en) 3-aza-bicyclo[3.1.0]hexane derivatives
EP2183246A2 (en) 2-aza-bicyclo-[3.3.0]-octane derivatives
CA2722347A1 (en) Piperidine and pyrrolidine compounds
WO2010038200A1 (en) Oxazolidine compounds as orexin receptor antagonists
WO2010004507A1 (en) Thiazolidine compounds as orexin receptor antagonists

Legal Events

Date Code Title Description
LAPS Patent lapsed